<SEC-DOCUMENT>0001193125-15-232500.txt : 20150624
<SEC-HEADER>0001193125-15-232500.hdr.sgml : 20150624
<ACCEPTANCE-DATETIME>20150624070434
ACCESSION NUMBER:		0001193125-15-232500
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150624
FILED AS OF DATE:		20150624
DATE AS OF CHANGE:		20150624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		15948238

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d949443d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of June, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 24 June 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g949443tx_pg03a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">423 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Graham Kelly</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman&nbsp;&amp; Executive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ian Phillips</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">24
June 2015</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><B>ANISINA ON TRACK TO ENTER THE CLINIC IN 2016</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anisina delivers potent anti-tumor effect in vivo</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human melanoma tumors respond to Anisina treatment</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potent anti-cancer effect with no observed toxicity </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><B>Sydney, Australia, 24 June 2015</B>: US-Australian drug discovery
company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (<B>Company</B>), announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by
the Company to come into the clinic.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Anisina targets the
cytoskeleton of cancer cells. This is the same target of the most widely used chemotherapy drugs in cancer, the taxanes and vinca alkaloids. These latter drugs are standard of care for some of the most common cancers in adults embracing both solid
cancers (breast, ovary, prostate, lung, bladder, testicle) and non-solid cancers (acute leukaemias, Hodgkin&#146;s Disease), as well as in pediatric cancers (neuroblastoma, Wilm&#146;s tumor). Beyond these approved uses, they are widely used
off-label across most forms of cancers following failure of standard of care drugs.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Despite their common use, the taxanes and vinca alkaloids come with the significant disadvantages of (i) being non-selective, resulting in
significant side-effects, (ii) not working in many forms of cancer, and (iii) readily inducing resistance in cancer cells.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><B>There remains a significant clinical need to improve on both the efficacy and safety of these commonly used drugs. Novogen believes that
Anisina has the features to meet that need across a range of cancer types.</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The taxanes and vinca alkaloids target a structural component of the cytoskeleton known as the microtubule. De-stabilizing
this structure prevents the cancer cell from dividing and promotes its death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anisina is a first-in-class drug candidate that targets the other main
structural component of a cancer cell known as the microfilament. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a 20-year history of attempts to produce drugs against microfilaments. The
commercial success of the taxanes and vinca alkaloids in the 1970s validated the cancer cell&#146;s cytoskeleton as a target for anti-cancer drugs, making the destruction of the microfilaments an obvious alternative drug target. These attempts
failed because of the inability to limit the destructive effect to cancer cells&#146; microfilaments, with loss of muscle function being a pronounced toxic side-effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g949443img_down.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g949443img_up.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The breakthrough came 10 years ago with the discovery by Professor Peter Gunning and Dr Justine Stehn at the
University of New South Wales (Sydney, Australia) of the role of a structural protein known as Tmp3.1 in the function of microfilaments. Cancer cells are far more reliant on Tmp3.1 for the integrity of their microfilaments than are normal cells.
Anisina specifically targets Tmp3.1, destroying the microfilaments of cancer cells with proportionally much less effect on normal cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compared to the
taxanes and vinca alkaloids, Anisina offers three potential advantages, viz. (i)&nbsp;being more selective against cancer cells, (ii)&nbsp;being able to kill cancer cell types inherently insensitive to taxanes and vinca alkaloids, and (iii)&nbsp;not
being subject to the same drug-resistance mechanisms that affect the taxanes and vinca alkaloids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ahead of bringing Anisina into the clinic, Novogen has
focused on three indications &#150; melanoma, prostate cancer, neuroblastoma &#150; with animal studies underway in each indication in support of IND applications over the next 9 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have previously announced that Anisina is active in vitro against human melanoma cells, a cancer that is relatively insensitive to the taxanes and vinca
alkaloids. We also have announced that Anisina kills human melanoma cells irrespective of their mutational status. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Today&#146;s announcement concerns the
important key step of establishing a significant anti-tumour effect in vivo. The study reported here is with melanoma; the neuroblastoma animal studies are being reported to a scientific conference on July&nbsp;13; the prostate cancer studies will
be reported shortly after that. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mice bearing the human malignant melanoma cell line A-375 (BRAF-mutant) were treated with Anisina either intravenously
(60 mg/kg/twice weekly) or orally (100 mg/kg/daily). Both dosing regimens delivered a significant anti-tumor effect with no observed toxicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justine
Stehn PhD, Novogen Anti-Tropomyosin Program Director, said, &#147;This result clears the way for Anisina to enter the clinic. The potent effect observed here of the drug on a cancer as difficult to treat as malignant melanoma, combined with the lack
of any obvious toxicity of the drug, justifies our earlier speculation that destroying a cancer cell&#146;s microfilaments would yield an equivalent therapeutic benefit to destroying the microtubules, but without the toxicity of the latter.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Large-scale manufacture of the compound now is underway with a target of being in a first-in-man study in 2Q16,&#148; Stehn added. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g949443img_down.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g949443img_up.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen
group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms yielding drug candidates that are first-in-class with potential application across a broad range of degenerative diseases. In
the oncology field, the ultimate objective is to see both drug technologies used in combination as first-line therapy across most forms of cancer, with the objective of preventing tumor recurrence. This objective is based on a strategy of achieving
comprehensive destruction of the full hierarchy of cells within a tumor with the super-benzopyran technology platform killing the tumor-initiating cells and the anti-tropomyosin technology, combined with vinca alkaloids, to deliver a potent chemical
debulking effect on their daughter cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.novogen.com</U> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Contact</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Graham Kelly</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Chairman &amp; CEO</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Graham.Kelly@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4101</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kym Robins</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Communications and PR Manager</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kym.Robins@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4109</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section&nbsp;21E of
the Securities Exchange Act of 1934.&nbsp;The Company has tried to identify such forward-looking statements by use of such words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148; &#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of
identifying such statements.&nbsp;Such statements include, but are not limited to any statements relating to the Company&#146;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Company&#146;s drug development program, including, but not limited to, Anisina, and any other statements that are not historical facts.&nbsp;Such statements involve risks and uncertainties, including, but not limited to, those risks and
uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company&#146;s drug components, including, but not limited to Anisina, the ability of the Company to
procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, Anisina, that could slow or prevent products coming to market,
the uncertainty of patent protection for the Company&#146;s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Anisina, and other&nbsp;risks detailed from time to time in the filings the
Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.&nbsp;Such statements are based on management&#146;s current expectations, but actual results may differ materially due to
various factions including those risks and uncertainties mentioned or referred to in this press release.&nbsp;Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g949443img_down.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g949443img_down.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g949443img_down.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.@+&`P$1``(1`0,1`?_$`,H``0`!!0$!`0$`````
M```````%`@,$!@<(`0D*`0$``@,!`0$`````````````!`4!`P8"!P@0``$#
M`@$%"0D+"08&`P````$``@,$!1$A,1(3!D%18=$RDC-3!W&!D:$B8G(4%4*R
M(W.3TS24-38(L5*"0X-4M%4W\,'")'1%TF.SA'65%D9V$0`"`0("!0D$!P<#
M!0```````0(#!!$Q(5&1$@5!87&!H3(3,P:QP5(T\-$B0G*R->%B@I)#<P>B
M@Q3"(U,D=/_:``P#`0`"$0,1`#\`_N,UTO6R<]W&@&NEZV3GNXT`UTO6R<]W
M&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UTO6R
M<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UL
MV?628#.=-V`[N5`:Q?\`:RR6FCJA7WVD@D$62(56NJ,=)N00P&672[RV1I59
M]V+P(E:_LK?SJL$]6.+V+2<2N/;%9J;%MOBNER=E`>7>I08[F69SYB,?,4B-
ME5>F3214UO4=I#10C.H_Y5VZ>PT6X=L.U%3BVA;2VQAR`LUM7/A\94N,6/<C
M"D1LJ4>\W)[/855;U%>ST4E"G'HWGM>CL-'K]JMI;H[2N%]NE3EQ#'5DS(FG
M<T88G1Q-PX`I$:5.'=BD5-:\NKAXUJDY=>C8M!&>T;C^_P!;]:G^<6S!:D:?
M$J?%+:Q[1N/[_6_6I_G$P6I#Q*GQ2VL>T;C^_P!;]:G^<3!:D/$J?%+:Q[1N
M/[_6_6I_G$P6I#Q*GQ2VL>T;C^_UOUJ?YQ,%J0\2I\4MK'M&X_O];]:G^<3!
M:D/$J?%+:Q[1N/[_`%OUJ?YQ,%J0\2I\4MK'M&X_O];]:G^<3!:D/$J?%+:S
M*I+_`'R@E$U'>;I32C#RXJZI:3AF!^$P<.`XA>94X26$DFCW3N+BE+?I3G&7
M,V;M0=K6V%'HBHJXKG&,,16L<)2/CZ9T#R>[I*/*SHO+%/F+6CQ_B%+ON-2/
M[RT[5@;S;^V>BE+672@N%&<`'34E2*N('=.KD,$P'.*C2L9KN-,M:/J6@]%>
MG*+UQ>\MFA^TWJW[=;.W/1%+?X6R.R"&KFDHIL=[0J=6"3P$K1*A6AG%X;2U
MH\5X?<:*=6*>J7V7VX&SMJ)G-#VSR.8<H>V5SFD',0YKBTXK26"TK%9#7S]=
M+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C0#7S]=+\H_C
M0#7S]=+\H_C0&U6::8T;L99#\*_.]V]'PH"5UTO6R<]W&@&NEZV3GNXT`UTO
M6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT`
MUTO6R<]W&@&NEZV3GNXT`UTO6R<]W&@&NEZV3GNXT!B55=-3AF#GN<_$C&1^
M``.!QP.)*`C'W&M?D]8D8,^#'.;XP=+QH#&U\_72_*/_`.)`-?/UTORC^-`-
M?/UTORC^-`-?/UTORC^-`-?/UTORC^-`?6SS:0^&ESC]8_?[J!9GCK:"MK__
M`)!?&MK*W)>+B&M;4U&0>N3`!K0_,%>4TO#C^%'S*\G-WU5;TL/$ERO6RU3T
MNT53@8G7(-.4/DJ9X6X;^,DK5ERIK/`4Z%U4[JGASMKVLLW#LTI+_B^^/QD=
MGFI:NOAK1ERGUJEJ:5VD.$N"S"\G2\O+JPV,TU_35"^TWB6.M.2E_,FO>:?<
MNPS9BUTE9=*:[;5U+J6,U!H[CM%<9J,QLROC8V"6GFRYQIN?O*1'B=><E"2@
MDWFHI,JKGT1PJUI3N*=2XENK'=G4DXZ.AI[6R'HBZW1:F@EGI(LF+(*FH9CA
MFTCK2YY[I*V2^V\9:61*,8V\=RA]B&I-F9[1N/\`,*[ZY4?.+&['4C=XM7XI
M;6/:-Q_F%=]<J/G$W8ZD/%J_%+:Q[1N/\PKOKE1\XF['4AXM7XI;6/:-Q_F%
M=]<J/G$W8ZD/%J_%+:Q[1N/\PKOKE1\XF['4AXM7XI;6/:-Q_F%=]<J/G$W8
MZD/%J_%+:Q[1N/\`,*[ZY4?.)NQU(>+5^*6UCVC<?YA7?7*CYQ8W8ZD/%J?%
M+:R&N5OI;P#[1%14.(PUPK:V"H&3`85%/412@CNK9&<X=QX$.YM:%W\Q'>>O
M%I[4TS0;CV:P5&DZV[4;4VMYQ+6.NU57TX)\V>9D^'[0J5"]G'O0A+JP^FPH
M[GTU1JXNWKW%.7XG)=KQ[30+EV<]H=)BZW[1375@Q(:R\5]%4=S554VJ)[DB
ME0O;9]Z.Z^A,HKCTWQJEIH5O%7-.47L;P[3G]RI]O;/B;D=J*1@)&MDJ;BZ`
MX;HGBF?"1^DI,)V]3N.#V%%<6_%[1_\`L*X@M;<L-J;7:0?M^^'->[M_[.M^
M?6W<AJ6Q$/\`Y-Q_Y*G\TOK!O]\`)]M7?(,?M*MW/VZ;D-2V(.YN4L?$J?S2
M^L]K;`_ALKKW9;-?]I^TC:)L5WMU%=([98IJB)T4-=!'4Q137&OGFTI6QR`.
MT(`,<Q.=<[<\9\.I*E1I1QC)K&7,\,ET:S[%P+_&\[RSHWW$;^LHU:<9[E/'
M0I)-)RDWITZ<(]9Z&V>[&.S_`&=,<D-MN%VJH\,*O:"]W6\2:0]V(*BJ%"QQ
M/YL("JJO$;NMH<DHZHI+]O:=_8>C/3W#\)0I2JU%]ZK.<^O!O=_TG5XI98(V
M0PR2111M#(XXWN:QC6C`-8T$-:T#,`H+TO%YG3QA&$5&*PBEH2T(V6T5%0:>
M7&>8_##/(\^X'G+3/,F4,B7;55+#I,J)VG?;*\'Q.7@WF='>;@SE3NE'GN=C
MS@04!+4=UEJGF,ZQC@W2Q$KBW)GSG$>-`2.NEZV3GNXT`UTO6R<]W&@*A++@
M_P"%DY(]V[\YO"@+*`(`@"`(`@"`(`@"`(`@.;WSM/L%HGEI*5D]WJ87.9)Z
MJZ..DCD;D+#528ZPAV0Z#7`'=4JG:5*BWGA%<^91W?'[.WDZ=-2JU%JT)=;S
MZD<[N':YM!4:3;?26^VL/)=H/K9P-SRYRV'']FI4;*DN^VWL*:MZCO9Z*,84
MUT;S[='8:+<-I+_=<?:%XKZEKL\1J'QP=P00ZN$#]%28TJ<.[%(J:U[>7'G5
M)R6K'!;%H-9KA_E*CT"3@,IRC',O9%-*0!`$`0!`$`0!`$`0!`$`0!`$&9)4
M-YNUL(=;KE6T6!QPIZB6-A]*,.U;N^"O,H0GWDF;J5Q<4/(G.'0VC>+?VJ[4
M4FBVJ-%=(P`#ZU`(93^VI3$<<-]KE'E9T998HM:/'^(4G]O<J+G6#VK`WVU]
MKMGJG,BNE!4VQSL`ZHB>*RE:3DQ<&MCJ&,!W0UV"C3LIKN--;"XM_4=O4:C<
M0E!OE7VE[GV,ZM#-#4PQ5-/+'/3SL;)#-$X/CEC<,6O8YI(+2%#::>#S.@A.
M%2"G3:<'DUD7%@]!`$`0&UV8849)W97X<.&KS>!`2J`(`@"`(`@"`(`@"`(`
M@(NYYX/1?[X("+0!`$`0'PD-SG#^V]G0%HS-')!/=R<:`MZY^(PP;X_RH%F<
M8K*>"*X5[XX(HWR5U4][V1M#WO=/(7.<\#2))5A%MQ2>6".5G"$;FHXQ2;D^
M3G+*R9"R"&VB^P;Q_H)O>KU3\V'3]1"XC\C6_ML\^JV.$"`(`@"`(`@"`(`@
M"`(#[B<",<ASC</=&8A!S<AK=SV0V8O&D;A8[?-([//'`*:IQW_6*;4RD]TE
M;85ZU/N2:7TUE?<<*X;=::]&FY:TL'MC@SGUT[%]GZALCK9<+A;'D'1CE,=?
M3@X'<D$51A^T*DPXA57?2EV?384=SZ0L:B;MJE2F\,GA)>Y]I^B>Q]JEM^R&
MRM"9&3FCV<LU,9&@QB0PV^GC+PQQ):':&.&)7*UIJ=>I+7-O:V_>??>$6TJ'
M"K:ECO;EO3CBN7"*6)..:6G1<"#O'^V4+43\M#S*4!L=G^CR_'?X`M-3O$JA
MD2R\&\("4M/TD_%N_*$!LB`("IN9_HCW[4!2@"`(`@"`(`@"`(#Z`2<`"3O`
M8E!F8<U?;Z>9M/47"@IZA^&A3U%;2P5#\<VA#+*R5V)W@LJ,FL4GAT&N5:C3
MDH5)PC-\CDD]C>)?J0X4U0<",:><@Y<#\"_*#NI'-=)FIY<OPOV'B$*_1\M/
MJ`(#X1CD.4'(0=U`14]HII27,+H2220W`MQ/FG,.X4!&RV6H:?@WQRCOL=N;
MCO)\:`P):.HAY<,@&_H$MYS<6^-`8R`(`@"`(`@"`(`@"`(`@"`(`@/5/9N2
M=C;5B2<'5K1B<<`*VHP`W@%47?GRZ?<=_P`#_3*?\7YF;PHQ;%Z.GGEZ.*1^
M.ZUA(\.&"`D([-5OY>A#FY9TCEX&8[B`D8K+3LP,LCY3NM`T&8][%Q\(0$NQ
MC8VM8QH:QHP:UHP``W`$!4@"`(`@"`(`@"`(`@"`("+N>>#T7^^"`BT`0!`$
M!A/.+W8[Y'@."`H0!#*S.27#Z=6_ZRI_ZSU/AW5T'+U?F)_B?M,->SR$!#;1
M?8-X_P!!-[U>J?FPZ?J(7$?D:W]MGGU6QP@0!`$`0!`$`0!`$`0!`$`0!`=)
MLW:CM!:J>FHYH:&Y4E+%'!"V>-T%0V&)H9&SUBG<W2T&``%S''?Q4.=G3FW*
M+:DSHK/U+?VE.-&2A4I122Q6#P7.O>F3EX[?-DK'04U9M)0W6V12UD5)ZQ1P
MLND4<DL<L@+F1&&JU6$1Q(C<1O+7#AE>K)QHN,FECI>'[";=>N>%VE*-7B4*
MM.+ENXQ6^D\&^3!X:-3-DV=[5>SC:K5ML>V5BJ9Y,-&BJ*QMMK\3[DT5R%)4
ME_`&E:*ME=T/-IR2UX8K:L2SX?ZI]/<3P5G=T93?W7+<E_+/=?8=DLP+J>31
M&EI2@MT<H<-`96D8XCN*OJ=XZBAICBLF;#'05<N:%S1DRR>0!CZ6!7@WF='9
MW'`RS!N^(VEQYSBT>)`25-104QTF:1>1@7N=CDX`,`$!F(`@*FYG^B/?M0%*
M`(`@"`(`@"`Y!VD=MVQ?9A5P6R^"[5UXJ:-M?#;+51LD>*6222**6>KJIJ:D
MA;))"X`:3G>3CAFQFVUA7NH[\-U4\<,6SF>.>K.%<`JJWN_$G<RCO*,%R/0F
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MMEDO\0`#I&QRVBM(!P)UM(9:5SB!U(4RIPN@_+<HO:B#;>N.)T7NW4*=:*Y>
MZ^S1V';-EOQ(;%[0UM%;*^WWBP5]?404D!GCBN%`ZJJ)&Q0QFKI'":-KY7`!
MSX0!CE(4*KPVM3BYQ<912QU/M^LZ:P]:<,O*D:-6%2E5FTEBE*.+T+2M/7@>
MA3D)!R$9".%5YU^)\6`?4`0!`8\M+33#X2&-W#HAKM[E-P*`CY++3NZ-\D1P
MR9I&]\.P/C0$=+9JEF)8Z.0;GE:#O`X:./?0$?)2U,720R-X=$EO.&+?&@+"
M`(`@"`(`@"`(`@+L<$TO1Q2/X6M)'APP"`D([/5OY>KB'G.TCW@S2_*@/7'9
MA98!L9:3++)(=.NQ:T!C3_GJ@9\7.P\"J+OSY?3D.^X%^F0Z9?FD=*CH:2+`
ML@CQ:<0YPTW>%^*C%N97!N#,!D`[@&0(`@"`(`@"`(`@"`(`@"`(`@"`("Q/
M3LJ``XN:YN.BX8'#'."#G!0$<^WRMY#FO'#Y)[F7$>-`8KZ>:/*^)X&_AB,O
M",0@+*`(#!?RW>D[\I0%*`(969R2X?3JW_65/_6>I\.ZNA'+U?F)_B?M(JIK
M*2C;I5=53TS<^,\T<?#D#G!QR;P6Q1E+NILTU*U&DL:LHQ7.\#6JO;>PTV(C
MFFK7C)A2PNT"1_S9C$S#N8K;&WJRS6"YRMJ\:L:?=<IOF7O>"-,O.W$]RI9Z
M&FHV4M/4L,<LDLAFG=$3Y36AK61QEPW?*(4BG;*,E*3Q:*B\XS.YI2HTX*,)
M+!MO%X>Q=IHJE%($`0!`$`0!`$`0!`$`0!`$`0!`<D[9_NG2_P#G*/\`AJU3
MN'^>_P`+.7]6_IL/[R_+(\O$`YP#AE&(QP/`K@^;X)GZJ?@.EFF[.ML]=++-
MJMLHF1:Z5\NK9[#HCH1ZQSM6S$XX#`8KC_422N88?![V?H?_``_.<^!W6^V\
M+I)8MO!;D<L<CW$N?/K00!`$`0%3<S_1'OVH"E`$`0!`$`0!`?G#^+G^IML_
M_'VS^/NBZ7A/RC_N/W'P[_(_Z]#_`.:'YIGEM61P(0'T`N<&M!<XYFM!<X]Q
MHQ)60M+P69/4VR.TERAD]6M-4&NBD#9:EHHXB7,<!Y=28L1CO`K7XU*#^T_>
M3:7"N(7,'X5*6ZUF_LK:\#F=K[";Q-HNO-ZH*!N'E14,4MPGRG$C6/\`5:=I
M'`7*7+B,/N1;Z='UD*AZ0N:CWKJK""U13D_<O:=9V0['=C[7>K-43MK[K4P7
M2W3,DK:HQ0B6*KA>QXIJ1L#3HO:#@YS@H=>^KRI22PBMUY?6=%PWTQPRVNJ4
MY*=2HJD>\]&.\N18'Z`BEI8RX,IH&C2.:)F.<[I:2N?<I/-L^PJC1AHC&*70
MBF2DI91A)30/'#$P'PM`**4EDV8E1HS6$HQ:Z"-FL%!)B8Q+3G#]6_2;CZ,F
ME^5>U5FL])$J<.MY=W&+YGH[<2)FV<J&XF">*0;@D#HG>$:;?R+8JT>5$2?#
M*JTTY*73H(J:VUT&.LI9<![I@UC>=&7`=];%.+R9$G;5Z??@\-J[#"S'`YQG
M&Z%Z-'+ARA`$`0&/)24TW20QD_G!NB[-ARFX%`1TEEIW98Y)(N`X2-\!T7>-
M`1\MFJF8ZMT<HX#H.\#LGC0$?+2U$/2PR,X2TX<X8A`6$!=C@FE.$<4CSYK'
M'PG#`("0BL]6\8O#(O2<"</19I(#/BLD0RRRO?P,`8,>Z=(E`2,5#20X:$#"
M1NO&F<=_R\4!E=S`<`R#P(#Z@/4W9I]S+5\97_Q]0J>[\]_3D1WW`OTRGU_F
MD;VHY;A`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`6GPQ2<N-I._A@?","@,9UN
MB>?(<YA./G-S;QR^-`0,U(]LCP"UV#W#>S.(W4!;%-(<^BWNGBQ0%]E(W$:3
MR?*&0``8=TXE`LSQ-M;M%>G[07ZD%PGBIX+O<:>.*G+8`(XJN5C0YT0:]QT1
ME).5=!0HT_"C+#%N*]A\FXE?WDKRM3\22@JDE@M&A2>HTASG2.+WN<]YRE[W
M%SB3G)<XDG%24DM"*AMR>,FVSXLF`@"`(`@"`(`@"`(`@"`(`@"`(`@"`Y)V
MS_=.E_\`.4?\-6J=P_SW^%G+^K?TV']Y?ED>7U<'S<_4_P#`5_3K;?@VUBQ_
M]%1+D/47S,/P>]GZ%_P[^AW?_P!:_)$]S+GCZX$`0!`$!4W,_P!$>_:@*4`0
M!`$`0!`$!YR[9>P>A[4;M3;0P;426*[TEKBM@@FH6W"W5,-/-//"YPBFIZJG
METZAP<07@C#R1AELK/B#M8.E*.]!O'4SB?4WHV'J"YC>TZ[I7$::C@X[T6DV
MURIIZ>?H/,M1^%C;JDE?K+A:*^E:XADEI?)+4R,&.#_5J]M!JW'>TGJR7%K:
M62DGS_6CAI?XYXS3;<ITIT_W,6]DMWWF*.R.W6-P;>;;=Y)6G+[2;-2P$C>9
M"R)CACY[E[_YDJGEM8<PCZ7M;.6%U&JYKXL8KLPT=9L-%:[;;FAM!04=(-^"
MGC8\\)ET3(X]TE:I2G+3)MEE1M+6@O\`L4X12U+WYDDR&>J+HZ>&:ID+7>1!
M')-(<A]S&USEY;4=+T(DJ,JF,::<I89+3[#6J'83:BOT2+:ZDC/ZROD92C#?
MU;BZ?-YB]NO2BL\2)2X3?U<'N;L=<GA^WL-YLW9B^EJ:6LN-U8YU/-%4>K44
M#BUSHGB1K'5$Y:='2;EPCQPS+3.ZWHN,5FN4M+;@3IU(U*U1?9:>$5JTYOZC
MK9RDG?)/A40Z-Z0A@(`@"`L34U-.,)H(I>%[&D]YV&D/"LIM9-GB=*E46%2,
M6NCZ,BYK!028F/6TY\Q^FT?HR`GQA>U6FL])#GPVWEW,8O;[2*FV<J6]!/%*
M-YX=$[_&T^$+8JT>5,B3X967ERC)<^A^]$3-;JZ#++2RAOYS6ZQG.C+@MBG%
MY-$2=M7I]^$L-OL,/=PW1G&Z.\O1H"`(`@*-!F?09COZ(Q\.&*`JPPR#($!]
M0!`$`0!`>INS3[F6KXRO_CZA4]WY[^G(CON!?IE/K_-(WM1RW"`(`@"`(`@"
M`(`@"`(`@"`(`@"`(`@"`("IG*'?_(4!`S=++\8_WQ0%M`$!Q?;'L;M^T%;4
M7:SU_L>OJWOFJH)HG5%!45#\KYVACFS4LDKLKL--I)QP"GT+Z5*.Y-;T5EK^
MFPY7B?I>A>U97-M/PJTGBTUC%O7K6/+GT''+IV/[<VW2=%;X+M$T$Z=KJHY7
MX#=]7G]7J">`-*GPOK>>;<7SG,7'IGB]#%Q@JD=<&GV/!G/*VW7"VR&*XT-9
M02`X%E933TSL=X:YC`[O8J5&<9K&+3125:%>@]VO"<)?O)KVF&O1J"`(`@"`
M(`@"`(`@"`(`@/A(&<@=U`2E%9;O<2!16ZKJ`<NFV%S8OEI`R(>%:Y5:<.\T
MB31L[JX\FG.2Z-&UZ#;*3LXOT[0ZHDH:''W$LSII!W6T['L'.4>5[2B\%BRS
MI\`O9K&HX0Z7B^Q/VGRK[.;_`$XTJ=]%7[S(9C#*[@:RH;&TG])9C>TI9XHQ
M5X!>PTTW"?0\'V_6<OV_['^TO;.ST]HV=V1N5;6LN]+/()334--'`V"K8Z=U
M973T],8FND&5KG'+F4ZTO[2A4=2K-*.Z^?L6DYGCWICC_$[6-M96M25554WC
MA%);LECO2:6QC9+\".WE>^&;;/:K9_9FE.BZ:DM(GVANH9G=&UVC0VR*7#)C
MK96@[A7JOZAMX:*$)2EK?V5[WV(C\-_Q#QBLU+BEQ1MZ?*H8U)]'W8I];/T.
M[-NS79;LIV8@V5V3I98J-DKJNMK*N03W&[7&5K&35]PG:R-CYGMC:UK6M;'&
MQH:T`!<S=W=:]K.M6>EY+D2U(^U\"X#P[T[8+AW#8M4D\7)O&4Y/.4GHQ?,D
MDEH2P-^48N0@"`(`@*FYG^B/?M0%*`(`@*'O9&`7N#0<V.[W!G*`Q75K!R6.
M=OX^2/[R@+#JV4\D-8.`8D=\XCQ(#&=)(\XN>X]_)X,R`H0!`?'M;(PQRM;)
M&1@8Y&MD81O%CP6D=Y$VM*S,-*2W9)..IY&N3['[+5,WK$U@MCI<<2YM.(FN
M.?%T<19$X]UJVJO66A2>!"EPSATY[\J-/>Z/<M!-14E+1021T=+34D8BD`92
MP14[<-!VY$UN*\;TI2^TV]))C2IT8.-*,8K#D27L.-*>LCG'F%DP$`0!`$`0
M!`$`0!8,EB:EIJCIJ>&3A<QNESP`[QKTI263-4Z-*IWXQ?414VS]!)B8C-`[
MS7ZQG-DQ/@(6Q5IK/!D2?#:$NYC%[?:14VSE4W$PS0S#<#M*)_CTV>,+VJT>
M701)\,K)8PE&79^PA:BEJ*5^KJ(GQ.W-(9'#?:X8M<.X5M4E+(@U*52E+=J)
MIEA9-80!`$`.0%QR-&=QR-'=<<`$&*6EY`90'#*TY0X96D;X(R$(.?D"`]3=
MFGW,M7QE?_'U*I[OSW].1'?<"_3*?7^:1O:CEN$`0!`$`0!`$`0!`$`0!`$`
M0!`$`0!`$!3(]D4;I9GLAB;E=+*]L431ONDD+6-'=*+3H69B345O2T17*S0;
MSVJ]GU@<YM=M-033QXXTEL<^Z5)(')#:%LT;7>DYJE4[*YJ]V#PY]'M*:Z]0
M\%M&XU;B#FN2/VW_`*<5M9JE5VG4$S6SVVVU4S:A@GB=7.;2>1,-8S2A9KI`
M=%V48A9_XLD\)-=1K?'J,H*="$FI)-;VC/3EI9K%5M]M#.3JI*:C9EP;3T['
M.&._)4:YQP[RV*WI<N+(-3C%Y/NN,%S+WO$Q(]M-I6.TO:1DS>3+3TKFG-D(
M$(SKUX-+##`UKBE\OOX]2^HGZ/M(KF8-K[?35(R8R4SWTTF&[Y#M=&3S5K=M
M'[K:)E+C=6*PK0C+G3P^LVNBV\L%5@)I*B@><,14PET8W_A8#(/"`M,K>HLL
M&6%+C%G4[SE!\Z]ZQ-D94VN[PEC)J"YP.&6(FGJV$'/I0OT\.^%JPG!\J9.4
M[>YC@G"I!\FA]AI]U[+MA[KIF6QQ4,SSB9K5)+;W@[^JB)IMW=C*WPN[B&4F
M^G25EQZ?X1<Z945">N#W>Q:.PYO=.P.G=I/LFT$L60EM/=:5LS<=P>M4AC<`
M.&(E2H<2E_4CL**X]'0>+M*S3U37OCA[#G%T[(MN;9I.9:X[K"T$ZVU5,=2<
M!NFGDU%5FWF%2X7UO/-X/G**X]-<7H94U4CK@\>QX/L.>UE#6V^0PU]'5T,H
M)!CJZ>:F?B,XPF8S%2HRC)8Q::*6I2JT9;M:,H2U237M,5>C6$`0!`$`0&?0
MVNXW-Y9;Z*HJW-Y6IC+FLQS:<F2-F/"0O$ZD(+&;21OHV]>X>%"$IM:E[\C<
M*+LYOU1HNJGT=O8<XEE,\P'Q=.',Q[KPHT[VE'1'%LM*7`;VIIJ.$%SO%[%]
M9MM%V:6F+`UU965KMUD>A21'O-ULI'Z04:5]4?=27:6E'T_:Q\Z4IRU+[*][
M[3>;7L=;Z;1=;[%"'##_`#$D&L?W=?5%QR<!4>I7JR[\BYM^%4*?R]%)ZVL>
MV1MT.SU4X#72Q0M'N6XRN`PS`#18/"H[FBTC8U7WVDMO["4BL%$S`RF6<C/I
M.U;.;'@[#OKRYOD),+&C'O8R).*EIH.A@BCPW6L&ESR"[QKRVWF28TJ<.Y%(
MS&$XYSFW^$+![,R.JJ(\-"5X`W"=(>!V(0&8RZRCI(V/]'%A_P`0\2`S&7*G
M=RM.,^<W2'A;B?$@,UDL<H)C>UX&?1..'=&<("M`$`0%3<S_`$1[]J`I0!`$
M!%5G3;N89\V;W/!_>@,1`$`0!`$`0!`4NY#\W1OY7)Y#L_`LK-&)=U]!Q-W*
M=FSG-FSG-P;RL%DN@YAYOI/BR8"`(`@"`(`@"`(`@"`(`@(7:'[/'(Z:+I.7
MN]!P[_FK92[Y`XE\OR=Y?1&CJ4400!`6I>CDZ7,>AZ7,.B\[>X5E9F)=UY]6
M9Y)[4?I4W]2>5_OGV+RQT'F?FJXM,EY75F<#QOOOYO\`C[G47>ROZ3#_`%)S
M_P"S?87[;S-]+S+^EUYFS@7F1^;_`(.YUGK*/D,Z3DCI>ES?K//W^%5+RY.H
M[F/7UGK'L[^YMFZ'HY^AS?2I^D_Y_P"?YV*H[GYB69]"X)^FT\N7++-]NOGQ
M-T6@M0@"`(`@"`(`@"`(`@"`(`@"`(`@"`(#&K/HTWTWD'[/^F_]OYZRL^3K
MR-=7RI=_+[O>ZCPCVJ?:4W]2NE_^Z?9V<]!YN]P+I+3+^EE]W,^2>HO-E\_G
M_7RZO<2?9UR&?</..3]L<H9O.WE&O?\`=_Z2Q].Y+Y#J\P[9=OHS?L?HV_:/
M+S'H^%5\.OJ.ON_+7E9?>SZCFLO+=T>?]3T?Z/`I*R.?EWGEGR9=1;63`0!`
M7:;IV=/RA]%^D;G1^=O+#R/4.^L^K/J.[;+_`$5OWCY/^\]%^R4"KWON]1UM
MAY?]?^/W&UK26(0$1M%]FR?8/(=]Y_L[-^5;*7>^]_#F1;[R'Y/^[W#Q+M;]
MJ3?=;EN^ZWT//N\*OZ/=^_\`Q'RCB/S#^7S?D]TU9;RO"`(`@`SK#R,K,[UV
M=?=MO1_3ZOH^5RF]+YWYOFX*JO?.Y?=U':\!_3E^.7MY?=S&]#..[NYN^H9<
M&U6CDC[+_1^D[GC7B63SS+.TR_I]69LIS[O?SK46!\0!`$!6S/WO[P@+J`(`
<@).V=.[XIV;TV<K^Y`3J`(`@*FYG^B/?M0'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g949443img_up.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g949443img_up.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/@+&`P$1``(1`0,1`?_$`,H``0`!!0$!`0$`````
M```````%`00&!P@#`@D*`0$``@,!`0$`````````````!`4"`P8!!P@0``$#
M`P`%"`,*"0H%!0````$``@,1!`4A,5$2!D%A<9&AT1,'4J(4@;'!(C)RTG,5
M"$)B@K(C,R0T-I+"0U-C@[-TM!94-76U=I0E11<W$0`"`0,!`P<(!@@%!0$`
M`````0(1`P0A,1(%05%AD:$R!G&!L<'1(A,S0K(C%#0U\.%B<J)S%0=2DL)#
M)/&"4W06H__:``P#`0`"$0,1`#\`_N*)-3I.L\IVH"E3M/64`J=IZR@%3M/6
M4`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@
M%3M/64`+BT%SG;K1I+G.W6@#E+B0`$#:2J]AB'$'&'#.,LKMEYFK+Q!$:P6\
MOMD]:@T\*U\4@]-%MC8O3[L70@WN)X&/\R[&O,M7U*II'(^;V'@JW&XV]OW:
M0)+A\5E#4<N[^GF(KS-4B&%<??:2*F]XDQX_A[<YOI]U>MF#9#S7XGNZMM!9
M8MAU>SP>/,!SS71E%><-"D1PK,>]67Z=!57O$&?<^7N6X]"J^MU]!@U_F\OE
M7;^2R5Y>FM:7$[WL!&K=BJ(F4KR`*1&W"'=2157LG(R'6_.4WTOU;",69H"`
M(`@"`(`@"`NK6^O;&036=W<6LHU26\TD+]&US'-)',="\E&,E2231G;N7+4M
M^U*49<Z;1FUAYF\66):)+R'(Q"@W+^W9*ZFSQXO!GKTN*CRQ+,MBIY"UL\=X
ME9TE-3C^TJ]JH^TSC'^<5J_<9E<--"=`=-87#)F`^EX%QX3@/[PJ/+!EMA)>
M<M;/B6&S(M-=,77L?M,YQ_'W"62W1%EXK:1QH(L@U]D^IU#>E'@FO,\J/+&O
M0U<:KHU+6SQGAU_9<49<TO=].AEL4D<[!)!)'/&1420O9+&0=1#XRYO:M#JM
MI91E&:K!IKH=3[0]"`(`@"`(`@,KPI_8W?6O]Z-`2U3M/64`J=IZR@%3M/64
M`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@%3M/64`J=IZR@+
M2[N7P-;NZ7/)`))H*4Y!2NM`13[NX?H,A:-C/BCLTH"WJ=IZR@%3M/64`J=I
MZR@%3M/64`J=IZR@*@FHTG6.4[4!QQQ&U[^),\UK7/<<SDJ-:TN<:WDW(`2K
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M:*2]!>+PVA`$`0!`$`0!`0^2X?P>9!&4Q5E?$BF_-"WQ@-7Q9V;LS:<SEG"[
M<M]R31%R<'#S/Q5J$WSM:]>WM,!R/D_PO=;SK";)8AYT@0W'M=N#R?HKL/DI
MT2!2HY]^/>I)=7H]A19/A3AMYN5EW+4NA[RZI:]I@.2\F>(;?>=B\G8Y)HJ0
MR9TN/G(V4>9X"?RPI,.(6WWTUVE'D>$,ZWKC7+=Q<SK%^M=I@&2X0XLQ`<Z_
MPN2BB::&>*)UU;[:^-:F:/=YR0I4,BQ<[LE7J])19/"N)8GS[-Q1YTMY=<:H
MQDO>"6ES@X:""2"#L(.D%;BO])0O<`3O.T"ORCWH#N#R]^ZKA,S@<'Q%Q/Q5
MEIQF<;995N+PT%O91P17L$=RRWEO[L7DTKVQR`.+(XQ74N;RN-W;=V=FS"*W
M9-5>NS39H?9N`_VPPLW!L9_$<FX_C6XSW+:44E))I.4MYO;K1(Z*X>\B_*GA
MIT4MAP?87=U$!NWN:?/FKG>'X8^T))K=CB?0C:%57>)9M[2=QJ/,M/0?0<#P
M3X7X<U*QB0E<7TKC=Q_Q-KJ2-KQ1QPQLBAC9%%&T,CBB8V.-C1H#6,8`UK0-
M0`HH3U=7M.G5N$4HQ244M$M%U(R7#_N\WUP_,6BYWO,2\=))T)AKWL.\QSFG
M:TD'L6!(+Z/)WD>N7?'XXJ:;-X4=VH"6LLDZZ>8G,W7;A=O-<=W00#H.GEVH
M"3J=IZR@%3M/64!4$T.DZMIVA`4.L])]]`40!`$`0!`$`0!`$`0!`:NSOFKA
ML9/+:8ZVER\\+GQR3,D;;V+9&&A:V8MDDG`<-):W=V$J9;P[DUO2>ZNTH,OQ
M!C6).W8B[LTZ5K2/7JWYEYS7=_YK\47=6V@L<6PU_=[?VB8`_P!M=F5M:<H8
M%)CAV5WJO].@IKWB'B%SY>Y;70JOK=?08-?YO,90DY'*7U[4U+9[F5T?N0[P
MB:.AJDQMPCI&*7F*F]DY.1\^Y.?E;IU;""O!^R7``_HG:`-A!.@<P69H,*.L
M])7@*(`@"`(`@"`(`@"`(`@"`(`@+NSO[['O$EA>75F\&N]:SRP&O/X;FAWN
MKR48R5))-&RW=NVG6U*47T-KT&;8_P`SN++'=;+=PY*,"A9?V['O-/[>'P9J
M\Y<5'EB69;%3R%I9X[Q&SWI*:_:7K5&9WB_."RF?'%F,5+9@T#[JRE]IB;^,
MZWD:R8-KZ+G'F4:>#)*L'7REOC^)+4FHY-MQZ8NJZGKU-FWK6ZMKVVAO+.:.
MXM;A@E@FC.\R2-VIPY1S@Z0=!4)IQ;C+1HZ.W<MWK:NVFI6Y+1GNO#,(`@"`
MRS#`BR)(T.E?3GIN5/14("40!`$`0!`$`0!`$`0!`$!&9+5#TO\`>:@(I`$`
M0!`?+G-;K/?U(#R,XT[K3S50'F9GDZ*#H'?5`C3M]'''D,@YD<;'/O;ISW,8
MUKGN=/(7.<YH!<2=JGP;<57F.7NQC')N427O/DZ2U69X$!$9_P#Y%E_\A/\`
MFE96_FP\OL(?$/P5[^5+T'/:MC@P@"`(`@"`(`@"`(`@"`J"1J)'0:(>D+D>
M'<#EPX9/#XZ\+M<DMK&)^D7$89.#T.6<+MRWW)-><AY&!@Y7XBU;F^=I5ZU1
M]IK_`"?DYPK>![K&3(XF0@T$,XNX!H/]%=M?)3F$@4J&??CWJ2\NGH*/)\)\
M,NINR[EJ70]Y=3U[3]!N#,0_&\'<*6#9FS^Q\.X>V$A;X1D\&P@CW]W>>&;V
M[6E31<M?G\2_<GSS;ZW7UGWC@V*\?A.-93WMS'MQKLK2*52><US#NN%#S\O0
M=16HL'5.CT/E#PR/#?N\WUP_,"U7.]YB38V,EEK)`0$GB?WH_5/]]J`R5`$!
M4:CT?"$`.L])]]`40!`$`0!`$`0!`5#2=0)IKH":=*'M&]ACMYQ?PECKIMCD
M.*>&[&]<0T6=WG,9;W)<30`PRW+9&DD\H"V*S>DMZ,)./D9!N\3X;8N?!OY%
MB%U\DKD4^ILFW/9-:2S0O9-"^WE<R:%[987@Q.H62QES'`[05BDU))[:DIN,
M[3E%IQ<7JM5LYT<2'6>E7R/EH0!`$!&SXNUF)<&NB<:FL9`!)Y2T@MZJ("-E
MPD@J89F/'('M+'=8W@@(^7'W<7RH7D;6C>'JDH"S((-"""-8.@H`@"`(`@"`
M(`@"`(`@"`(`@"`ZF\M/X.QO-+>TYOVN95.7\]G>\!_+(>67UF9VHI<%U%97
M4U/#@D(.IQ;NMZ=YU&H"_BPEP[];)'$-@K([U:-[4!(Q8:UCH9#),=CCN,K\
MUNDCW4!*M:UK0UH#6@4#0``!L`&@("J`(`@"`(`@"`(`@"`(`@(S):H>E_O-
M0$4@"`(`@+%_RW?./OH#Y0!#U;34N1_?KW_.7/\`C/4^'=7D.8O?B9_O/TED
MLS`("(S_`/R++_Y"?\TK*W\V'E]A#XA^"O?RI>@Y[5L<&$`0!`$`0!`$`0!`
M$`0!`$`0&>X?S(XGQ$%O:":VOK.VC;##!>P!SF0L%&1MN(713[K&B@J74"BS
MQ+,W752?,7F'XAXEAP5J,HSM)))26Q+DJJ/M9+YW[P>%X<QMO?\`$F"R#(GW
MT%HZ;#20WGANFCF=XAM[I]I(6#PM(#W%:[?"[EZ3A:DFTJZZ>@EYOCS$P;$;
M_$;%Q0<U&MMJ5*INM&XODYV37#WGMY3\2[C++C+'6-R^@%GG1+A+BII\4.R#
M(;9[JG\&1RU7>&YUGO6VUSQ][T$[A_C?POQ'2SEVX7/\-RMM_P`:2?F;-]<.
MS0WMI)+930WL3I6ELMI+'=1N!C!!;)`Z1A!&G05674U*C33.QQ+EN[#?M2C*
M#V---=:,ICQEX_28Q&*5K(X-]45=V+62R^CPS?Z6<GFC9_.<?@0$E!9V]N=Z
M)AWB-TO<XN=3E&P5/,@+E`$!4:CT?"$`.L])]]`40!`$`0!`$!H_S4\]^'/*
MN_M</?8G+9K,7F/;DHK:R-O:VD=M)++!";B^N7.+722P/^*R.0@"II4*?B\/
MN94?B*2C;3IK[#D_$/B_!\/7HXMVU<NY4H;R4:))-M*LGTI[$SESB#[W?'=_
MOQ\/83`<.1&H;-,R;.7P'(=^Z-O9M=3^P(5I;X3CPUN.4GU+LU[3@,S^Y'&+
MVF%:LV(\[K<EVT7\)HWB'S2\Q.*M]N=XRSUY!(276<=[)8V%#^"+&P]EM=T;
M"TJ=:QL>S\N$4_)KULY+-X_QKB-5F95Z4']'>W8_Y8T788"6M))(!+M+B14N
M.TDZ25OJRGHGM)[$<6<4<->)+P]Q%FL*\1R:,;DKNUC/Q':'P1RB"0<SFE82
MM6KM%<C&7E1+Q^(9^"G+"O7;3I]&32ZJT?G1KG!_>/\`,G%&-E_<8OB*W8:.
M;E+!D5T\5T_MN.=:2%U.5S7J;=X;C2?N)Q?0_:0,;QEQG&>[=<+T%_B6O7&G
MK-U\*_>;PF8OK#&9SAR_Q%S?W=M91W5A<Q9*Q;/=2L@B=(R1MK>1QF5X!(;(
M0#50;O#)P3E;DI)+8]'[#I\#QQBY-V%C*LSMW)R44XM256Z+D3IUG4%#4BFD
M$@TTT(T'5SJK.X*$$:Q3I0!`$`0'E)#%**21L?\`.:#VZT!82XBTDTM#XC^(
M:CG^*_>'O("/EPD@TQ3,=HU/!:3[HW@@(^3'WD5=Z!Y`Y64>.GXM4!9T-:4-
M=G*@"`(`@"`(`@"`("YBL[J;2R"0CTMVC=)IK<0*("0CPMP[]9)'&-@J]W91
MO:@.M?*_#6K>#<89'22N\6^K4AC/WR8:`WXW)M51EO[=^8[W@/Y9#RR^M(V;
M%;6\/ZJ&-A](-!=_*=5U5&+@]D`0!`$`0!`$`0!`$`0!`$`0!`$!XS01SM`?
M44TM+30BM*ZP00:("P?CG#]7('#8\;IZP7`H"U?:7#-<9(VM^,.RI0%N01H(
M(.PZ$!1`6+_EN^<[WR@/E`$/5M-2Y`$WU[33^UW.KZYZGP[J\AS%[\3/]Y^D
M@;O+XNPWO:\A:PENMAF:Z7H$49?(3[BVQA.7=39$NYF+9^;<BGS5UZEJ8Q=\
M?8>&HM8KN]<-3FL%O$3\^8^)3\A;HXUQ]ZB*V[QW%A\M2F^I=;]AA^6XVR&3
MMY;.*""SMYVEDVZ73321DBK#(_=:P.`H:-KSK?#&C%J3=6BHR^,7\FV[48QA
M;EH^5M<U=G888I)4!`$`0!`$`0!`$`0!`$`0!`$`0&IO.;^$8/\`K=C_`(%X
MIO#_`)[_`'7ZCF/%OY7'^<OJR.72`=!%1L*N3YL?J5]P?1Y?\>@:AQG:4'(/
M_8;;5L7(>(OQ-O\`<];/T'_9W3@N8EL^]1^HCNM<\?7@@"`(`@*C4>CX0@!U
MGI/OH"B`(`@"`(`@/SE^]W_^DX?_`,/Q_P#W/++I>$?@W_,?H1\1_N3^>V__
M`%H_6F<KJR/GP0'M!;W%T_P[6":YD]"WBDF?_)C:XH]%5Z(RA;G==+<7)]";
M]!E5KP!Q1?1NK8"R8^-]'W\K+>E6.`)B'B3^HM3R+,7MKY"SM<#XG?BVK>Y&
MFV3IV:OL-;8SR%`W79OB$[76^*M=&O2/:KP]HB4N7$JZPAU_J(5CP>G[V7>\
MT%ZY>PVKPKY6<$8C+8F6/$F^N(LE82,GREQ+>.;(RZB<U[8JQVS2'`$?$T%0
MKV9D3MR6]14>S0Z'AWAWA.-DVY1M[UQ7(ZR;?*N39V'>VY&PD,C8P5.AK&M&
MOF`5"VZUY3ZXHQCI%)(H^..0%KXV/!T$/8UPZG`I5K5"4(25))->0C9L-CIJ
MGP/"=M@<8].W=TL[%FKLURU(L\#&G]'=?0Z$5-PUK-O==#9F?SX_HK8K_.B)
M/A;_`-J?6O6B*FPN1AJ?`\5HY8'-DT?-^*_L6Q7(/E(D\+)A]&JZ-?U]A&O8
M^,[LC'QNV/:YAZG`%9II["*TXNDDT^G0^4/`@"`\WQ12BDD;'_.:">LBJ`CY
M<19R5+6OA)_JW:!^2\."`CY<)*-,,S7\SP6'K!>$!'RX^\B^5`XC:RD@]2J`
MMO#D_JWCI8X?!SH#VCLKJ7Y$$AYRW<;_`"G[H0$C%A9W4,LC(QL;5[@.7D#>
MU`7\6&M6?K#)*><[C>ING7SH"0CM;>']7#&T[0T%W\HU<@/=`$!U)Y9_P;C/
MKK__`%LZJ,OY[.\X!^60\LOK,SU1BY"`(`@"`(`@"`(`@"`(`@"`(`@"`(`@
M"`^7,8_Y;6N^<`??0%NZQMY#0-,9/*PZ-7HFH0&/S6A$D@:\&CWCXPIJ<1R5
M0'F+5YUN:.BI/P!`>S+6,$;Q<[2.8=FE`</<997)R\2<06S[^Z-O#F<G#%`)
MG,B9%'>3,8S<86M(:T4TU*Z*Q:MJU%I*KBCY'Q7*R9Y]^W*<MR-V:2K144GS
M&'<M>4ZSRGW5OV;"J"]`0!`$`0!`$`0!`$`0!`$`0!`$`0!`:F\YOX1@_P"M
MV/\`@7BF\/\`GO\`=?J.8\6_E<?YR^K(Y=5R?-C]2ON$?P!Q[_YG:?\`8;;O
M7(>(OQ%O]S_4S]"?V=_)LS_VH_41W6N>/KH0!`$`0%1J/1\(0`ZSTGWT!1`$
M`0!`$!0D#22`.<T]]`:+\UO)+A/S1O;?+Y#+9?$9NSQ[<;!=8[V>ZM9+:*::
M>)MS8W+-U[F2SN^,R6,D&AK0*=BY]W%B[<4I6VZZ^TY/Q#X1P?$-Z.5>N7+6
M5&&ZG&C5$VU6+Z6]4T<YW'W2\G;RO?!Q3;92V!K'"RT.+O'-]%[KB6\MFOZ'
M45BN,6WHX-/RU1QD_P"V>1;;<<F-R',H[CZVVBR?Y,,X<&]>\*7MQNZ3=78D
MR4)W?PJV[GVK1HY6A9K-^+W9K7S&/_REK!UNXTY4Y95DNSW>PN(88+5HBMX8
M;9HT>'#''`!310L8UE*<X7C;>W4D0A9MK=MQC%+D2IV$K9X;+9.K<=C+Z\):
M[3;VTKV:CKEW1$T=)"URN0CWFD2;5B_?JK$)STY$WV[#'[+RUXCNJ.N1:8UA
M_P")G$LH%=/Z*V$NGF+@MCR;<5I5D:UP3-N4W]V"Z75]2J9KB?++'V4\%U>Y
M&YO98)8YF1PQLM;??B<'LWB3-,]H<W55M5IGDRDG%)),M,?@=FU-7+DY2E%I
MZ*BTZV;-)J:[5&+T(>!`$`0'R]C)!NR,9(W8]K7CJ<"FS8>2C&:I-)KIU(V;
M#8Z:OZ#PB>6%SF>K5S.Q9JY-<I%G@XT_H[KZ-"*FX;Y;>Z_)F9_/C/\`-6Q7
M^=$2?"WMMSZU["+FPN1AJ?`\5HY87"31\W0_L6Q78/E(D\'*A]&JZ'7]9&/8
M^-V[(Q\;O1>US#U.`*S33V$5IQ=))I])\H>!`$`0!`$`0!`$`0'4GEG_``;C
M/KK_`/ULZJ,OY[.\X!^60\LOK,SU1BY"`(`@"`(`@"`(`@"`(`@"`(`@"`(`
M@"`(#Z9\H>[[Q0$#-^ME^L?^<4!YH`@-7<7>4_#_`!3=2Y*.:?#92?XT]S:,
M9+;W4E*>+<VDCF`S&FE[',+N6I4RQF7+*W>]!?IM.>XEX<PN(7'?BW:R'M:U
M3?.T^7I372:?RGD9Q3:;[L9>8S+QMTM9XK["Y<-GAW(=`7?WJG0XC9EWTXOK
M1S.1X1XC;UL2MW5Y=U]3T[36^4X2XGPN]]J8+)VC&D@S.M7RV^CE%S;^+`1^
M4I4+]JXO=DNLH\CAN?B?B+-R*YZ576JKM,=!!K0@TT&G(=A6X@E4`0!`$`0!
M`$`0!`$`0!`5:USW!C&N>\ZF,:7N/0UH)*\;2U>P]2<G2*;?09%9<)<17]##
MBYXXW:I;K=M(^G].6/(Z&E:99%F&V2KT:D^SPO/O:QMM+GE[OIU,LM/+&^>V
MM[D[6W=_5V\4ET1TO<;=O551Y9T5W8MEE;\.WVOMKD8OH3EVZ%;GROR/_P`=
MD+>[?R13036[R=@='[0WKHD<Z+[T6D>S\.9'^Q<4WS-->BIK[C7R!\R^-\5!
MA<5C,?:3-REK=27>8RUK8V++>.*Y8^0/:9[B4AT@^*V(N.Q3,;B>)CS=R;;6
MZ]$JLH.->"_$'%L6.)CVX1DKBEO3FHQI22Z6]NQ*I?<)_<(?OP7''/F!&8P6
MNGQG"6-<YSVZW1#,99S0RNK>;:&G(O;WB-4ICV]>>3]2]IJX=_9V58SXOF^[
MRQLQU\F_/9Y=P[PX)X&X7\N^'K3A?A#%Q8K$6A=)N!SIKF[NI`WQ[[(7<I,U
MY>SEHWGN.H``!H`'.Y&1>RKKO7G6;ZO,N1'V#A7".'\$PH\/X9;5O&CK3:VW
MME)O64GRM^:BT,M6DL@@"`(`@*C4>CX0@!UGI/OH"B`(#SDE9$/CG2=(`TFE
M:5IR:4!9NOO09[KC\`0%NZZF=^%N\S13MTGM0'BYSG&KB7':34H#Y0!`5!(U
M$CH0%A+C,9/()I\;CYI@:^++96TDE=N^^(N/6LE.:T3=/*S3+'QYRWY6X.7.
MXIOT%X:-B<QH#6-C>&L:`UC1N'0&BC0%XN\GRFR5%!I;*&DE8+8<R]H7IX$`
M0!`$`0!`$`0!`?+V,D;NR,9(W3H>UKQIUZ'`HFUL/)1C-4DDUTD;-A<=-4^S
M^$X_A0N,?J_&9V+-79KE(L\'&G]&CZ-/U=A%3<-ZS;W70V9G9OQG^:MBO_XD
M1)\+_P#'/K7K7L(*\L+JQ($\=&N-&2,._&[F#@!1W,0"ML91ELVD"]CW;#^T
M6G.MA9K(T!`$`0%K=WUECXS+?WEI8Q@5W[RYAMFTV@S/8"LHQE+2*;?087+M
MJRMZ[*,8]+2](M+VRR$8EL+RTOHB*^)9W,-RRFTN@>\#W4<91TDFF+=VU=6]
M:E&4>AI^@NEB9G4GEG_!N-^NO_\`6SJHR_GL[W@/Y9#RR^LS/5&+@(`@"`(`
M@"`(`@"`(`@"`(`@"`(`@"`:]`TH".R68Q.&C=-E\IC\9&T5+K^\M[71M#9I
M&O=[@*RC"<W2";?0C1?R<;%CO9-R%M?M-+TFL\EYX\`V,AAL+O(<1W8J&V^!
MQT]T'.U!HN)Q;P:=K2Y3(\/R7K.D(\\G0H;WBS@]M[EB5R_<YK<6^UT754AK
MWS(R$D;)[;!/Q_M+&S-&4\5TT7C#?#'QL9!'OLK0C>.E8K&A765?(9SXW?=M
M3C9<-Y)^_6JKR-*FOG,4NN,.([HG>R<L#3^!:-CMF"NPQM\0^ZXK:K-I<G65
M]SB>;<VW&ET:>@M&<1YZ-V\W,9"OXUS(\'I:\N:0LOAVZ4W50UK-S([+L^LG
MK/S`SMO1MP+6^8*5\:'PI2.7]+`6"O2TK6\>V]FA,M<9RX*D]V:Z51]:]AE5
MGYC8V6C;ZRNK1QUOA<RZB!Z/T4H'N%:98TEW6F6%OC=B7S82B^C5>IF5V7$F
M$OJ-MLI;%SOZ&5_L\NGD,<XCJ>856F5JY':F6%K.Q+VD+D=>1Z=C+7*<'\+9
MMI=DL!B[IS]/M#;9D$YKRMNK3P92>?>*RA>O6^Y*2_3F9KR.&</RU6_9MR?/
M2CZU1]IK;*>1G#%UOOQ=_D\3(:EL;G1Y"V!/XDXCN`T?6J7#B-Y=])KJ*+(\
M(X%RKQYW+<N;22[:/M-<Y3R-XJM-Y^-N\9EXQ4AK9GV%R=@\*Y:82:;)5*AQ
M&S+2:<7UE'D>$N(VM;$K=V/EW7U/3M-;Y3A/B;"D_:F!REHP5_3.M9)+<TY1
M<0"6`C\I2X7[-SN23\Y19'#<_%_$6;D5STJNM57:8]4'45M(15`$`0!`$!-8
MKA[+YK>=C[-TL3';C[A[F0V['4!W3+(YH+J'4*E:KEZW:[[)F-@Y67K8A6*Y
M7HNMF;67EC>O`=D,E;V^V.TC?<O`V>)(88P:;`5%GG16D$WY2WL^';LM;]R,
M>B*J^MT1EUAY></P$;]O=9*31HN)7EM=6B&V$0ITU4:69>?*DBTL<"P8;8RN
M2Z7IU*AGN/X8=;-#;+&6]BP`4<(HK<TYR!XKO=4:=URUG*K+NSPYP5+-N,%Y
M$OUF01<.DZ;BZ'.V%A)Z-^0C\U:M_F1-C@?^2742<.&Q\5"83,1IK,\O%?FC
M=9V+QSDR3'$L1Y*OI))C&1C=C8R-OHL:&#J:`L"0HQBJ122/5FL]'PA#TN62
MR1_(D>SYKB.P&B`NV9*Y;\HMD^>VAZV[J`O&96,_K(G,YVD/'4=TCM0%_#<0
MSU\)X<1I(-0X#5J-"4![(`@"`J-1Z/A"`J0*G2-9V[>A`4H-H[>Y`*#:.WN0
M$/=#].^IV4KO:J#5HU("WH-H[>Y`*#:.WN0"@VCM[D`H-H[>Y`*#:.WN0"@V
MCM[D`H-H[>Y`*#:/=K3W:BE$!KG(VO#DLLC[7*>ROWCO1&VNYX-ZNGPW,AJU
MO07#9H4N$KJ6L:HI+MO#<JV[E'S4;7FT,=FACC=2.Z@N!R.C9<MZQ-;Q$=JW
M)UY&B)*,4]))KS^M(\*#TAZWT4,10>D/6^B@%!Z0];Z*`4'I#UOHH!0>D/6^
MB@%!Z0];Z*`4'I#UOHH!0>D/6^B@%!Z0];Z*`4'I#UOHH!0>D/6^B@%!Z0];
MZ*`B\T!]F7%7-_HMW>K\KQF:JMUTJL[?S%S$//I]TELK54\M?94P+='IMZG_
M`$5,.>&Z/3;U/^B@&Z/3;U/^BO0<_>9(\V'9:_'#[LBSAIL=O[,<,(#<O_9H
MS<F3V5K\KHN"\:0T4U:-*L,7[GN+XM/B]/Z4.4XO_7?CR^Z[_P!THJ;E*[%6
MM/>VU]1S/DF9'VIWVS+>>VU._P#:@OO::UTU]LC\76K:.[3W*;O13U''7E=W
M_P#D.7Q/VJU[=3UP\-])>1MQ%W/!=DC=DL&Y0S`UV8RUFN#U+RXXJ/OJJZ:>
ML]L1NNY2PVI_L[U?X54[&\H,3Q2W-XYW'G%.3?PH8[DWL5SC+L78(MY#:MCG
MOK(9<!UR&@EL3M!.H:51YT[7PG]WA'X_)JJ=CH?0/#UG.^]P_JMZ?]/H]ZL7
M79IK);^VFQ>4_1K"C%?9-C]B.@^R?`;[%X&_N&*IJ3OM$GB%]=_?^/O5WM*Y
MFYO[[^)WZZGVC$^[_=X?=*?=Z>[3]*[=M=:DI0;1V]RUD@4&T=O<@%!M';W(
M!0;1V]R`4&T=O<@%!M';W(!0;1V]R`4&T=O<@%!M';W(!0;1V]R`4&T=O<@%
M!M';W(!0;1V]R`4&T=O<@%!M';W(!0;1V]R`4&T=O<@(_(7EQ9Q%]MBK_+24
MJV&QEQD))V.DR>0L&-KM%5E&*DZ2DHKIKZDS1?NW+4:V[4[DN:+@OK2B:PS'
M$WF[)O1\/^6ME:@U#;G,<286[EZ?9K3)VL+3S&1RF6[6$M;MUOR1?L*')S_$
MDM,/!C'IG=MOL4TNTTOQ:[[Q,T,DF4CS%K9FI=!PS["8VMV..`DNKS=`])Y4
M^S_2T_<W6_VJ_P"HY7B+\;2BW?5V-OFM;M/_`,VWVF#<(MX0#[IW'4A=GS>$
M1,SHRM1`(F4,OM$8BWS-O5\0UYJ+;D_>*)8ORJ?1I_U(/!UP>DGQM_\`.WW1
M7-_91;:Z;:[3?6*&(\%OV(<9X&B@Q?LVY3\;V4>^JBY\3>^UWM[IJ=YB_<MW
M_A?"W*?0W=G_`&F4-W3`SQMP,W`"):%E`-9WANZ1M6*Z-I.=-WWZ4Z3%,J.&
M3#.-ZS;=>%)X1M?$KXNZ=P.]G:Z/2[TM"VP^)R5H5>5_3]UTW?BTTIS^;0P*
M@](>MW+>4XH/2'K?10\%!Z0];Z*`H0VFES:<]:?FKT:&08@<2;S?L9V3I44]
MF]H]GU\M6^STKMT+5/X7T]VOFJ3,99M5]U^)YJT]AL2SNO,.`-]IQMI?,T?K
MY[&":G.^"ZCH>EA4=K&>QM=9=VKG&H?,MQG'I<4^Q^HRJSR&3EHV]P-S:.Y7
MQ7V.NHJ_^IAD`]PK2XP7=DGYF3[5[(EI=LRCY)1:]*9-"NZ=-!3XP-:`<N]0
M%M-O(L"5R=!K3BK_`.JOC_[F_P!LF<D[YBW/M$'EK]E#V[>Z05*L_>Z?9;^[
MV=I0<0_^<U^__`WJ<G>_@]XTME,+Y+W6^[%\89/$R&NZQ^+S&0M@>0;D^+BN
M-W^]*L(7,]=ZW&7G2]9RV1B^%KE7C9-RV_W)R7;!/M-<93$8BS)=C>*\7F(]
M-`S'9^PN.8&.ZQ7@5/UJEPG<EWX./G3]91Y&-C6G]AD6[L?W;D7U.%.T@-T>
MFWJ?]!;2&-T>FWJ?]!`>T$$<T@8^\MK5IUS7#;QT;>D6MI=2GW&E8R=%L;ZO
M6T90BI2HY1CTNOJ3?8=(\`X[#V^`A9_N"WOH_:KI[I;&QR<48>YS2^$&_L[>
M4^'J+O#`/(J;+E-WFW%I]+7J9W_`[&)#!2^,IQWY:QC)+;L]Y)]AL.W9PZQS
M1XK9'Z/C7(G#:]#XHXE%^TJ7UM8">C3?37UF10B#<'LY@W/[#=W?=\,46MUY
M2?#<I]G2G0>M!M';W+PR%!M';W(!0;1V]R`4&T=O<@/M@%?E#5^-S<R`]:#:
M.WN0"@VCM[D`H-H[>Y`2>,`\<Z1^J=M],<R`G:#:.WN0"@VCM[D`H-H[>Y`5
+`%#I&KGVCF0'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g949443tx_pg03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g949443tx_pg03a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`C0+&`P$1``(1`0,1`?_$`.```0`!!`,!`0``````
M```````%`08'"`(#!`D*`0$``04!`0$!````````````!0$"`P0&!P@)"A``
M`0,#`@,"!@@/#00(!P$``0(#!``%!A$'(3$2$PA!46%Q(A2!D;$R4Y34%?#!
MT4)2LB,S<[-4E=4V":%B<B0T=+0U5746=M9#9+66X6.3TT0E%S?Q@I*BPF56
M&1$``@$#`00%!P@(!`4#!0````$"$0,$!2$Q41)!87$3!H&1T2(R(P>AL<%2
M<K(S%$*2TG,T%34(\.%B=(+"4],6DR08HD.S)1?_V@`,`P$``A$#$0`_`/W%
M$G4\3S/A/CH"FI\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\
M9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@/+.
M),*5J3]Y5[HH"R*=72"Q<DW!L>/A<=M8NER&J?5(KB>S94"/Y5)!4AK16FJ4
M]2_(*V+6-<N;7ZL>+(C.UG$PV[<7WE_@MWE9@'(<QO>2.'UZ1V<1*^IFWQ]6
MHK1'O2I(]-]P?9+)/BTJ3M68652&\Y#-U'*SI/OG2W]5;E]+\K+8ZC]!5]6L
MIH#J/T%7U:`=1^@J^K0#J/T%7U:`=1^@J^K0#J/T%7U:`=1^@J^K0#J/T%7U
M:`E+5?+I99(EVV8[&>X!72=6W4@Z]#S1!;=1KX"#Y-*LN6XW(\LMQL8^5D8E
MSO<>3C/_`!T;C.F.;IVZ?V<6^-IMDHZ($M!)@.JY`KZM5Q"H_9%2>/,5'7,.
M4=MO;$ZO"\06+S[O,7=W/K?HM_1\IE5"T.(2XVM#K:TA2'&U!;:TGDI"TDI4
MDCPBM-IIT>\Z%.+7-%IQ?2MS.5"HH!0"@%`*`4`H!0%UV0GU-?X97N-_5H"6
MU/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`
MU/C/MF@&I\9]LT`U/C/MF@&I\9]LT!Q4X$#J6OI3XR3[0',D^*@(MZXJ/HLZ
MI!YJ(]/SIUY:^7C0$<5*))*E$DDDDDDZG7B:`IJ?&?;-`-3XS[9H!J?&?;-`
M-3XS[9H!J?&?;-"JWFG>4_K+D!/]L7#^DN?4J<M?A1^RCS'4')ZC>BG3WDOO
M$#P\OM_]%9#4Y9_6^0QYE^V..YAUOK:7;;ROWET@)`==5]:F9'X-S$C3GZ+F
MG)0K;Q\R[CO8^:WP?T,@-6\-8&JMSDN[S7NG'>_M+=)?+UF'QW?,HM\LN9%*
M:BV3K"6)L'K7(F!0)2GL70/F]9_ZW4Z^]!YUOO5;4XTM)NYP9R*\":CCW7+-
MDHX==DHU<I+K7Z/E,L63'K1CL7U2TPVXR5=)>>)+DF2M(.BY#ZR5N*U/+@D>
M`"M*Y<N79<TW4ZG#P,73[7=8L%&/2^E]KZ2:JPVQ0"@%`*`4`H!0%G9-@MAR
MA)<E,JB7#IT1<X>B).H'HA]/WN4@<M%#73D16:UD7;.Q;8<")U/1L+4TYW8\
MN1T3CL?EXKJ\QKKD^W^18R5OK;-QM@)*;C#0M24)_P![8U+D8^4ZH_?5+V<J
MU>V5I<X,X#4]"SM.DYR7>8]?;CM_66]=NXL3M%>`ZCP'CQ_=K9(0IVJ_'[OU
M:`=JOQ^[]6@':K\?N_5H"?QO&LDS"Y-VC&K3-O$]9&K41I2D,))T[67(44QX
MC">96XI(TK%>OVL>'/>DHKK-_3],U#5<A8FG69WK[Z(K8EQDW2,5UMHW@VX[
MJ=KMACW7<68F^3D]+B<=@NN(LT=0T(1/E>@_<BGPH2&VM>'I"N<R];G-.WBK
MEC]9[_)P/9O#WPOQ\?ER=?FKMU;>ZC^&OM2WS[$DNMFW4.)%@16(4*.Q$B16
MD,QHT9I####*!HAIIIL)0A"1R`%0,FY2<I-N3WM[V>JV\>U9MQM68QA:BJ))
M)))<$BZK.?N#_P"&3]H:P7/:\AO8RI%]I--NN-+"VUJ0H>%)TU'B/@(-6&R3
ML:[A6B9&J%<!VB2>@^521[TZ^Q0$N%]0!2OJ2>(4E6H.OB-`5U/C/MF@&I\9
M]LT!4$Z'B>7C/C%`4/,^<^[0%*`4`H!0"@%`*`4`H!0"@%`*`4!:66Y79,;M
MTLW&4/62PKLH#'2[,>/`C1K4=F@_9+*4UEMV+MSV5ZO'H-',U'$PHUNR]>FR
M*VM^@U0R;<>]7P+C13\TVY1*2Q&=5ZR\C7@),E)2O0CFE'2GSU(VL6%O;+;(
MY#-UO*RTX0K;LOH3VM=;^@QV3KS^CQD^$DUM$0W4I0H*`4`H!0"@%`*`4`H!
M0%U8]F-[QQQ(@R.TB$_=($DJ<B+'(E*=0IA>GUR"D^/6L%W'MW526PW\/4<K
M!E6S+W;WQ>U?Y>0SYCFX-DR#LXZUBV7)6B?5)3B>S>5IRB2?1;=.OUIZ5Z>`
MU'7<:=O=MCU(Z_!UK%S/4F^2]P>Y]C+[K7)<4`H!0"@%`*`4!=5D_D;GX9?V
MK5`2U`*`4`H!0"@%`*`4`H!0"@(VY'T61^^43Q/$@#0^P#0$30"@%`*`4`H!
M0JMYI[E/ZRY!_?$_^DNU.6?PH_91YCG_`-2O/HYY?>.NW6*;<-%A/81R?OSO
M#J'_`%:."ED^`\!Y:3NQCNVC'Q;]_P!:G+;X^A%]V^S0;:$J;0'7]"%2'=%.
MZ^'IT'2V#Y/;K7E.4MY,8^):L[4JRXO>=61MH=L5U2XD*"8;SH!&NBVD]HA0
M\1"A5;5>\36],IJ$8RPKO,JTMM^;::^U*G""@%`*`4`H!0"@%`*`<]00""""
M"`001H00=00:#?L,793M99+[VDJV]-DN*B5=3#85`D.'77MXB=.R)/US>GE!
MK;LYMVUZLO6A\OG.:U+PUA9C[W'2LY#K[*]5OKCT=J->,@Q2^8P]V5VAK;;4
MHAF8UJ["D#70%J0D=/41]:KI6/"*E;5^U>5;;J^&YG!9VFYNG3Y,J%(O=);8
MOR\>HMRLQI--;RA.@)\0)H49]=]F[%:;%MKA[=J@QX9N./VNY7!UEI"7ITZ;
M%:DR)4MX)#C[BG'3IU'1*=`-`*X//N3NYEQW&W2;2X))M?0?57A+!Q,/P[B1
MQH1@[EB$YM+;*4HIN4GO;=>G<E1&3JU#IA0%Q6;[P]^%3]I6&Y[7D-JQ[+[2
M7JPSB@)6TN+$@MA1Z%-J)3KP)!!!T\!H"XZ`4!4<CYOIB@!YGSGW:`I0"@%`
M*`4`H!0"@%`*`4`H"/N=VMMEC*EW28S#8`5TEQ8ZW5`>\8:&KCR_(D&KX0G<
M=(*IAOY%C&CSY$E&/ROL728-R7=>;,[2)CS2K?&/4DW!X(5.<2=1JRC13<4>
M(GJ7YC4A:PXQ]:XZOJW'*9WB"Y=3MX:Y(/8V_:\G`PU<GG7V);S[KCSSB5*<
M==67'%J)!*EK62I1]FMU))4CL1SC<I2<Y-N3WMNOSEC'F?.?=H4*4`H!0"@%
M`*`4`H!0"@%`*`4!77EY#J/&#IIJ#SIOW@R'C6X]ZL0;C2E&ZVX$)]7D.$2&
M$#0?Q:20I8``X)7U)\U:UW%MW-L?5D3&#K65ATA<K=LKH;VI?Z7Z>PSW8<JL
MF2-`VZ2/60D%V"^4M2VO&>R*CVJ/WR"4U&W+%RU[:V'7X>H8V:JV9>M]5[&B
MXO\`X?1XZQ;]IO"@%`*`4`H"ZK)_(W/PR_M6J`EJ`4`H!0"@%`*`4`H!0"@%
M`1ERY,^=?N)H"*H!0"@%`*`4!Q4M*.9]CPT!@"=8X2+[=ISJ?67G[G+>2ET`
MM-=;ZE)"6^*5*3XSKQ\`J2C<;MQCT4./N8EK\Y=N2VR<Y/;T5?\`C:>LG7P`
M:<.`TH9DDMQ2A4B;_P#U'=O[OE?BC5]KVUY/G-//_@KW[I_,S7JI4X,4`H!0
M"@%`*`4`H!0"@%`=3[#$IAR-*8:DQG04NL2&TNLN)(T(6VL%)%$VG5-U+;EN
M%V#MW8J5M[TTFC"N4;/19!<EXP\F&Z=5FU25J,1:N93%DGK7&//1*^I/E`J0
ML9\HKEOJJXK><=J/A*U.MW3&H3=?4E7E\DN@P%=+5<;/)<A72&_!DI!^YOH*
M>M/'1;2_>/-GP*22#4G"<+BYH.J.(R<>_B7'8R8N%U=#^CBNM'U^VS_]N<#_
M`,HV#_AL>N$R_P"+O?O)?>9]7>&_Z#A?[2U]R)>]:Q."@+BLWWA[\*G[2L-S
MVO(;5CV7VDO5AG%`25J_E8_!K^E0%S4`H"HY'S?3%`#S/G/NT!2@%`*`4`H!
M0"@%`*`4`H#%N;[B#'WU6FTMM2;HE/\`&GW=5L0"M(4ELM@CMI720="0E.O'
M4\*W,;%5U<]QT@]W^9`:IK?Y27Y?%2E?6]O<J_.S7VX7.X7:0J7<Y;TV0O75
M;RRH)!.O2TC@VT@>!*0`*DXQC!4BJ(XZ]>NY%QW+TG*?6>*JF(\L[^22"?`V
M?I4!91YGSF@*4`H!0"@%`*`4`H!0"@%`*`4`H!0':T^\PXAUAUQEULA3;K2U
M-N-J')2%H(4DCR&C2:H]Q=&3C)2BVI+<UO,R8ENA*0['MV1J$AA92TBZA.DA
MA1(2A4P)T0\SJ>*P`I(XG6M"_BK;.WLZCI=.U^XI1L9OK1>SFZ5PKQ7%[S/'
M`\4D%)XI(.H(/$$'P@BH[MWG7=FX4`H!0"@+JLG\D<_#*^U;/N"@):@%`*`4
M`H!0"@%`*`4`H!0$9<N3/G7[B:`BJ`4`H!0%"0.)X4!T+?YA'#P:\?<-`=!)
M)U)U/EH#$MS_`*QG_P`\D?C%5OP]E=AS5_\`B9]K^<\-7F,4!$W_`/J.[?W?
M*_%&K[7MKR?.:>?_``5[]T_F9KU4J<&*`4`H!0"@%`*`4`H!0"@%`*`C+O9[
M7?8BX5VA,36%@Z!Y/IM*(TZV'4Z.L.`<BD@U="4K<N:VVF:V7AXV;:=G)A&<
M*;*]'6GO3-P\1M+=NQ#%H40N&/$Q^U1V0XKK=#;,-EMOJ5H.L]*>)X&H&_)R
MOSE+VG)M_.>LZ5CQQM*QK-GV86(17&BBOH)KEP/,5B)"O04H"XK-]X>_"I^T
MK#<]KR&U8]E]I+U89Q0$E:OY6/P:_I4!<U`*`J.1\WTQ0`\SYS[M`4H!0"@%
M`*`4`H!0"@%`<5J*$.+'$H;<6`>1*$%0U]JJK>6R;46UO29I-)D.RY,B6^HK
M?DO.ONK))*ENK*U$D\3Q5PUJ>244HQW(\OG)W)RN2VRDVWY6=-5+!0'4\@.-
M.-JY+0I/M@Z>?C0%D.M*9<6VL:*2H@CW#R`T(-`==`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!2E=X-L<!FO3\1M#SZBMQMMV(5DDJ4F(^XPV5$\SV:0/8J'R8J-
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MM'-'LH!0"@%`*`4`H!0"@%`*`4!&7+DSYU^XF@(J@%`*`4!Y7EDJZ>`"0!P\
M/(ZGRT!TT`H#$US_`*QG_P`\D?C%5OP]E=AS5_\`B9]K^<\-7F,4!$W_`/J.
M[?W?*_%&K[7MKR?.:>?_``5[]T_F9KU4J<&*`4`H!0"@%`*`4`H!0"@%`*`4
M#-Q<7=;>QG'UM+2XCYIA-]22".MMA"'$ZCZY"TD$>`U!7?QI]IZWI4HST^S*
M+3CW<?D23^5'OEH`*71PZE=*@.7`:Z^SI6,V+RI1QV'DH6%Q6;[P]^%3]I6&
MY[7D-JQ[+[27JPSB@).T@F5KIP#:M3QX:Z`>V10%RT`H"HY'S?3%`#S/G/NT
M!2@%`*`4`H!0"@%`*`4!UO?>7_P#WXI=56]=I;/V)?9?S&D53YY8*`4`H#QR
MH3$H?=!HO0A+@X+3QU`Y:*2/$:`MR5;GX^I">T;UXN('+^$D:E/[HH"/*2GG
MIQH"E`*`4`H!0"@%`*`4`H!0"@%`*`4!M-MI^IMM_#S_`.F/5$YGX\O)\QW^
MA_TNWVR^\R^ZU26/CI^VT[I5Y[RW=*<S;#!=)N?=VV?=]SK7C<%<EYC*<1EV
M]B#N#;T6QHJ1*OEKL<)%QA+2@N],1]E/!\UR_BS399VG=_:J[UA\R2Z8O9+9
MQIM73P/J+^T[XD8O@;XC/1M4[N&DZ["&+*[)*MJ\I.6.^?HA.;=J:;I6<)/V
M#\.T-F1<)$.';HLFX3KA(C0[?!A1W)$N?,F/(8A0X;"$J7(DS'W4H;0D$K6H
M`<Z\GKS>K%-M[$N)^LMQPLPE=O24+4(N4I2=%%159-M[DDFV^A(_5WC7>%RC
M]D)L=LAW4L(L>)Y[OC-Q^7O'WCDYI-O=QL^`9IN2B%<;1M]C\*TW2`W`FV2R
ML-B8->A:@E[IZI"E5]5_#7X<PRM![[4YWK<7+9RM*LOTMZ?JK9'9ODFS^9W^
M_?\`O8R+7QNO8_@;$P<NW:M1MRE>4Z1L0JL:O=SBW=O+GR)<S?):G9A2ANKW
M"?VL64]Y+>]K9G>G%L!PQ[++/).W=VQ/YYBHG99;B9;V.707JZ7%+CMWM:7%
M0BWT$OL]F>HN)TZ#Q3X$L:-ISU'3KEVY&$UWBG1M0>Q27*EN>_8]AX1\#?[I
M=3^(GC1>$/&&+@X=S*LO\K.QWB4K\?6=F:N3E5W(*7=TH^>/+MYE3[BD:5YH
MMJ/M);54I0"@%`*`4`H!0"@%`*`4!&7+DSYU^XF@(J@%`*`4!XG/?J\]`<*`
M4!B:Y_UC/_GDC\8JM^'LKL.:O_Q,^U_.>&KS&*`B;_\`U'=O[OE?BC5]KVUY
M/G-//_@KW[I_,S7JI4X,4`H!0"@%`*`4`H!0"@%`*`4`H"XL?RJ]XT]UVZ42
MPI?6[!?U=AO:\^MDD="R/KD%*O+6&[8MW5M6TD,'4\S3I<V/+U'OB]L7Y./6
MJ-&;+=NIC,]F+'N\EC'[A*D,QF6[@^VW#E2G$N%#,28YT-]HYV9Z4+Z5$C0:
MU'3P[T&^1.44JNG0CL<;Q-I^1&,<J<;-Z3HE)TC)NM%%OI=.DOOR^`\0?&"`
M01Y"#6L3R:>U5+BLWWA[\*G[2L%SVO(;=CV7VDP`5'1())Y``DGS`:FK#.2\
M:TN*/7)/9H^#&A<//F>2/W30$XTRTRGH:0$)YD#PG3F22230'90"@*CD?-],
M4`/,^<^[0%*`4`H!0"@%`*`4!$WN_67&K<]=K_=(5GMK`)<ESWT,-Z@:]FT%
M'M'WE`<$-A2SX!5]NW.[+DMIN74:V7F8F!8>3FW(6K"WN3IYN+ZEM-4+[WP;
M'$O'JU@Q29>;*V[T/W.7.%LER4]72MR!;_5Y&C9'%/;*0H^$)J5AHUR4:SGR
MSX+Z6>=9?Q+Q+63R8>-*[BI[92ERM_9C1^2K5>E(V`PK=##-QK:Z_C5U;<F)
MBO+E66641KS"^Y*ZNVA*62ZTD_[1HN-GQUH7L6]C2]XO5KOZ&=EI7B#2]<QW
M/!N+O>5UMRI&<=G3%[^U5J:QU+HX84`H!0"@%`14NULO]2T?<G#J24^\/+WR
M.7'3F.-`6[(AOQ3HZ@Z:Z!8!*%>+17+CXCH:`\U`*`4`H!0"@%`*`4`H!0"@
M%`*`VFVT_4VV_AY_],>J)S/QY>3YCO\`0_Z7;[9?>9D%EAZ0L-LMJ6K4`@#@
MG7PJ)X)'#PUJDL8H[R&\.,=V/8W/]ZLQ+4UK%+0L66QEU+/^(\LNBO4,9QME
M1T+J[I='D!W3@F.EU?%*#4IHNEW=:U.UIMG?<EM?1&*VRD^Q;N+:1Q'Q'\<Z
M?\-_!>=XPU%UCBV_=PK1W;\_5LVH[:UE-JK6U14I=!^8%G]KSWN8[K4ABU=W
MUAUEU$AE+.QV+-!I;3@<0AE]"DR&PV4@)6E0<&FH/57LW_\`-?"RI2%ZJ6]3
M2=>-%$_.-_WJ?'R5>?/PW&6].Q)II[T_>[5T/J-;.^`%97N'$[QL.XS+EB/>
M=B2]S+9,N<U4V9C^8-OMVK<G;2XS'"-9>`9.RIB(@Z*59'H#@&BQ70>'VK&+
M_)Y14;^$U;:2HI0=96YI<)1]KH4U)=!X]\5ZZGK\?B!9G.[I?B.,LN$I2YG:
MOI\F7B2EL];%O)Q@J+_V\K$J)2+;[K&,L7K=.'GETO-PQ[`]BXJ-Z=P\GLLO
MU2ZVVQX5<(<JUV:PSDDI8RO-\G5#LUK',R9G7H4MJK-KE_N\)XD8J>3DONH1
M>U-R3JY+ZL(\TY/@C1^&>FPR_$L->RKUS'T/1(_S#*OVW2<+>/*,H6[4ENO9
M%[DL6>GGN<U*19N]</VU'?;F3Y\J#.VKM<27,ER(5L.W4*;\VQ7WW'(L`S7I
MX>F&"RM+9=6`ISHZCQ-<U'X;^'(P49+(<TEM[QJKXTIL3WTKLJ>SY']XWQEN
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MU9_AW=,VZVM:P=6_V_VQ%EWOW!SO++3,EX)M/@4:T8^UD.9'#;//@2[_`'O(
MLMOR+?8K3ZY&C%Q+KCSO9,E*JI*C;Z`=.Z&8]Z;NA6F'O-N)NWC/>1V)M-_Q
M^#O197MJ;-M?N'M[B^17F#87=Q<$NN+7FX6B^VG$YMQ:>N%KN+';*AE:VY'4
M@U1)-T0,S=TW>',]S(6\N";H2[1/W:V&WPS#;+*)ECMK=FMU^QF4XSE.U.70
MK4TMUN.QD^W]YB+*D$H<?:<4/"`=.@&M1[Y6[M^RG=:W[9V/$\L>S3O.O=U+
MNGV.\L/0,?7<]KL2=N^_^].X%_MJU7>[X1B%Q8EA,2+T+<5"3';6E;Y6E0&1
M=QK9WZ=EL/ON[]IWOP'O$JPFU2\JS'8R?LE;-M8F48Y9HR[ADEMVPS*P9+>+
M]9,FCVN.\[;479-P9E.MI:=*2O6J['L0.^X]Y#<3?S-<&VR[I5QQ#'8M]V5P
MC?\`W$WHW`QZ;E\+`<)W-[8;=8CCN#PKI98^0;C92S#E25^N36H-OAQ2M:75
M.(35O:#,>+8[W@=MK'N1?MR=^[%O';;=@=_NV+QCLW8MNKO9<DM%KN%R3*FW
M#'\BN,"]69UN,E'JRXK3B5:DNJ'"J^KU@Q3W8X_>NW5VJV'WMS'O'X\]:MP<
M(P/<3)<$MW=UQ>VL+AY%:X-WN.-0<K1ECD^&WTR2RW-#"G$C1?03PJLJ)@QA
MM)WMMVGN^#N3M1NPK&'=E,JWDW2V3V&OUILR+5<\8W*VGL^/98]@F97-+RV[
MO,S_``^_O2[2XL-N+>MCK:0KJX5<53KH#93!-T,LRKO%=Z';*\/6]S%=HU[)
M##6H\!N/<&1GVWKF29#\Y3TK*[CVET0"SU!/8M^B->=6TV5!GVJ`4`H!0'B<
M]^KST!PH!0&)KG_6,_\`GDC\8JM^'LKL.:O_`,3/M?SGAJ\QB@(F_P#]1W;^
M[Y7XHU?:]M>3YS4S_P""O?NG\S->JE3@A0"@%`*`4`H!0"@%`*`4`H!0"@%`
M8FWF`.'L@\1\^0/Q$VMW3_QW]E_0<QXM2>EQK_UE]V1:VVW>$S?;[L+>^\K)
ML;1TH-GNS[BGHC0X$6JY'M)$0`<FU=HUJ/>CG6;,TK'RO6CZEWBNGM1&>'O'
MFM:%3'NR_,Z<MUN;=8K_`$2WQ['5=1]-MDMP+#NW8KE>,>1/B-6VX1X5SC7)
MA+;T:8]$$D,LK;<=9EH#:O?I(3KX->%<AGX=W"NJ%VFU;*=)]!^%O$6#XCPY
MY."KB[N:C-323C)QYJ53:?:C/L>(S&'W-/I>%P\5GV?`*T3J#TZT`H!0"@*C
MD?-],4`/,^<^[0%*`4`H!0"@%`=;SS,9EV3)>:CQV$%U^1(=;889:3Q4X\\Z
MI+;:$CPJ(%$FVHK:V4E*,(N=QJ,$JMO8DNMFJFX_>GQW'R_:\#99RF[)"FU7
M9U2V\>AN:%)[(I*)%V6@_8=FT3]>:E\;2KD_7R'RPX=+]!YUKOQ!PL-O'TF*
MR,C=SO\`#79N<Z=5#17+,URC.+DJZY1>)=UDZJ[%#J^B'"022&8$)'3'B,I!
MTT2G4^$D\:G+5FU8CR6HI1/)=1U34-6OO(S[L[D^A-^JEPC'<EP^=EK5D-`[
M6)DNWNIG0)4F#,C)<<CRX;[L:0RL(40IIYE2'$'4>`U6D9+EFJQX%8W;EB7?
M692A>C6DHNC7E*X#WE;E;NPMF=QW+Q$3T-IOL)"4W5E/+KFQ?18N`3KJ5(+;
MOD4:OOZ;&7K6*1?!_0;>D^-;UEJQJD7.U]=>TOM+I\GF-P+#D=CRB`BYX_<X
MEU@K`U>BNI6IE9&O9263TO1GAX4K2D^2H>Y;G;ERS33ZST3$S<7/M*_AW(W+
M?4]W4UO3ZG0FZL-H4`H!0"@.*D)6.E0!2>8(!!\X((H"%E6A"R5QE="N)[-6
MI0=>?2KZT^3E0$`ZPZPOLW4*0KQ$<]/"D\B*`ZJ`4`H!0"@%`*`4`H!0"@.2
M4+4H(2E2E*.@2`23KXA0&X.U-G4K#+4Y)/2DOW#[DGWW":\-%*X@5$9?X\O)
M\QW^A_TNWVR^\S+333;*`AI"4)'@2--?*H\U'RGC6L2Q\_OVF?=FN?><[K>2
M6;%A.?S[;69_ZGX1:8C[J6\CG6*WRV;SC;T)*@Q,EW7'Y$@02L%3<U#820%J
MUZSP7K,=&UR%R[3\M>7=R;6V-6N62?0E*BEU-\#P+^Y+X<9/Q'^&F1C:;SRU
MO3I_G,>$6TKKMQDKEIQK24IVG+NJITN*-*59^+;H=X`,22LGI#?JS_:]>O2&
M^RZ.T[7JX=.G5U<--:^C&U1[J'X]\LZ\O++GW4HZUX4IOZC?/,]T<N[JN"X'
MW><*E61&;1%/;J[YN9)B&'YPS8=Q,\L]H39]NK/"S.R7^'8I&$8/"@IO*XK;
M3S]XE/-.J4(J`.5QL*SKF5=U?)4ORTJ6[/+*<.:W"3K<?)*/,IS;<*MTCM6]
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MCS8DME:`MF3$D-*0XDC5*TD5U$9QG!3@TXM5777=3M/$KMJ]CW98]^$[=^$G
M&491:E&46U)-;ZIIIK?54/T5;+=V&Z;"?LBN]/FN6-7&)FV_>U<G-Y]AE+?0
MU8<3B)C,83#7;5'H9NURMDM<Z4LI[4(DM,G[UI7@7CS7+>J:TK&/RO&Q:P4E
M^E+]/;P322[&^D_5[^U+X;97@7X=_P`YU57(:UKDH9,K<FTK5A1:QX\E:*<H
M-W9NG-2<(OV:&X/?/95W>'+7WM[8V^U@6>[#S>[-WG(4*.ZXRU9,CPRY,;'[
MLS&(R%*7(P7.YZ;+,>4E2DVN[CCTMUQ$>#/J`L[;>_H[N2NX[WF,TA7).R>7
M]QO;[NZ[IYI;[;/ND':2_6]5BS[;_+,R9MS$F7;L'OC\N?;I5Q[,LP9'8J>*
M4*"J/I[097[VG>!VL[QFSN2]UWNX9WBN]VZW>&B6_;Z-"VWN<?,;/@&&7RZV
M]69[G;A7RS&59\6QO%L99D/-^M/MR)DLLLL-K6O@2IZSW`QGWL]RSW!]]KSO
M=88LN?9.\5W7;OM7:X;;+SHN?>;V&M[2-BTNM,(7U7/-L;R)5O\`2])PP`-?
M1TJJ7,N%`3M^V=OG="VC[@^Y#-@OV9P^ZK/R-OO$,8Q;)=ZR9RS[^X;)M^[F
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M9/\`TWE9V]C_`*]Z_(<:%L^;^Q:7Z*6D](`K)NM.@%^8SL<]W@=N_P!H1@5G
MN1QS/H??KSS.MI,O2GIDX;N]@V.;;W[;_(FGATN(81>(HB2^E0[2!*?;Y*(H
M]K0/5^S_`-WSWA]VN]WN;*M$C&LHFH[ME@S[%YC#T:1B>YV&[8W/%=Q<7>0Z
MA!Z+5E=KD):5IHI@MJ'OJK))*BX@^F+C+C1Z7$E)\'A!\H/(@U8#KH!0"@/$
MY[]7GH#A0"@,37/^L9_\\D?C%5OP]E=AS5_^)GVOYSPU>8RBE)0E2UJ2A"!U
M+6LA*4I^R4I1`2//1;71;RC:BN:32B8VRK+8CL5^UVQ1?4_HW(EC@PEK7[HT
MR3Z3JEZ:=0T3IKIK6U9L/F4Y>RCG=3U2U.V\;'=6]C?13JXF+JWCFA0"@%`*
M`4`H!0"@%`*`4`H!0"@%`8GWF_5!G^_('XB;6[I_X[^R_H.9\6_TN/[Y?=D:
MN5,GFI]1>X/^H^X/^;[=_P`#37(^(_Q[?V/^8^@O@Y_2,W_<P^XC?"N=/7Q0
M"@%`*`J.1\WTQ0`\SYS[M`4H!0"@%`*`4!H#WO,CO7^*;'BR;A(:L*,?8NKE
MN:<4W'E3I,^<R7Y:$D)DEIJ*D-A8(1J2!J370Z1;@K$KE$YN=-O0DEN/&OB3
MFY7\PM:>IM8G<J;CT.3E)5?&B226Y;]^TT[J6/-10"@.#OWIW\$[^+555O+9
M^P^QFL"N9]CW!4NCD'O?:7EM[?KMCV88_+M$U^&X_>+9$E-MN*2Q-BR9C,=Z
M-,9!#;[*VG"-%`Z'B-"*Q9$(W;,HS2]E]J)+2,O)Q-0M3QYN,G<BGP:;2::W
M-,^J92>I24@G0G0#B>D$@<O-7*GO35)-+B4((X$$'Q$$'VC504H4%4`H!0"@
M.IUEM]/2ZD*'E`X'Q@\P:`MZ5:'$`KCGM!\&=`L>97)>OMT!#J0I*BDI4%#F
M"""/'J#QX&@.-`*`4`H!0"@%`/;^CZ=`2L6U//@+=!:;/C^^*_@I.G3[-`7%
M'BLQDZ-(T.@!7J>M6GA*N=`;7;9_J7;/YQ<?Z:[4/E_Q#[$=_H?],AVR^\R_
M*UR6*@D$$'0CB".8-`1XM%F"@OYDLG6%=87\SVWK"]>H+ZO5=>L*XZ\]:O[R
MY]:7G?I-;\EA5KW%FO[N'S\I^47]K%W,LJVU[QDW=+;?$<ER7`]^';GF#[.,
MV"[W\XON`V\R<SM4U-JB37(T6\RI*+G$4X$A7K3S:2>QKW/P+XCQ\S25@YER
M$,K&?+64DN:&UPDFVJM+U7UI'Y<_W1_"#4_#GQ"N>)?#^+D9&B:VYY#5JW.[
MW.35?F(2Y%*BG*2NPKT3E']`QG^S<[E68;Z=Y/&Y6XF%Y7CFV6UJX6X>7/9'
MCE[Q]F_2K3<&7,9Q*&[=84+UAR\7IM#DCLBI3<*.Z>!*:W?&/B3'TW1IQP[D
M)YE^MN/+)/E37K2V-[E5+K:X'/?V\?!S5_&OQ$QKVO8>3C^'-+<<J^[MJY:5
MR4))V;$7)1;=RY1SINMPGQ1^PAZUV=]UU]VRV5UUY:W777+1;7''''25.+<6
MJ,5+6M2B23J2:^?E.Y%44I4I3VGZ3]:'AX<I.<K-ES;JWW<*M\7ZO':>I;33
MK:F7667F%I[-;#S+;L=QL:?<UL.)4TIO0`=)'3IX*M-@HZRP^TMB0PQ(CNIZ
M'(\AEI^.X@$$(<CNI6RX@%(]%22.`\5`<DH;0UV"&F41^R[`QTM-ICF/TE!C
ME@)#)CE!T[/IZ-.&FE`>&V6BS61M]FR6:SV1J4OM9+5FM4"TMR7==>TD(M\>
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MYVSQ::;:+[Q`"GGRA*2\\M(`*U:J(`X\!0'!N/&96\XQ%BQW)+G:R7(\9AAR
M4]Q';2G&FT+DO'7WRRI7$\>-`=BT)6DI6D*2>8(H".?@?7,JU\/9JUX>1)H"
M+4E224J!!&H((\7.@*4!XG/?J\]`<*`4!B>Y_P!8S_YY(_&*K?A["[#F;_\`
M$S?15_.6/>LMMEIZFFUB=-&H]784.S;5_P!>_P`4H`\('4KR5L6[,YOA$A\S
M5K&+6$?7O<%N\YBF[9%=+RI7K;W0QKZ$1DJ1'1XM1KJZKRJUK>A9A!;%MXG,
M96=DY;I<E2'!;B#K*:8H!0"@%`*`4`H!0"@%`*`4`H!0"@%`8GWF_5!G^_('
MXB;6[I_X[^R_H.9\6_TN/[Y?=D:N5,GFI]1>X/\`J/N#_F^W?\#37(^(_P`>
MW]C_`)CZ"^#G](S?]S#[B-\*YT]?%`*`4`H"HY'S?3%`#S/G/NT!2@%`*`4`
MH!0'SE[W?_N3:/\`)]N_XE=ZZ/2/X67[Q_-$\/\`B1_7;?\`MH_?F:KU*'`"
M@%`<'?O3OX)W\6JJK>6S]E]AK/'BR9TEN)"CO2Y3Q"6H\9I;SSATY(;0"H^?
MD*EJQBJS:4>LY2%JY=N*%N+E*3V45>DV'VZV7F&\62YY3(,-+5UMLEJTPU)7
M**FIK#J!,D\6V4A2?20CJ5^^%1N5GP[N4+*JZ/;T>0[?1/"MQ95J_J,N6ER#
MY([77F6][O(?41#+,?J0PTVVC4^\2`3QYD\2HGRDURK;EO/>H6X6ERVTHQ.#
MT=B0DH?:0ZDC3TT@D#]ZKFD^:JIM;BD[<+BY9I-%L3L><2%.05]H.?8.:!8\
MB%\E^8Z&LT;WUB*OZ=**<K&V/![UV<2VU)4VHH<2I"T^^2M)2H><$`UGJGM6
MXC'&47RR7K%*%!0"@%`*`\LB(Q)'W1`ZA[U8X+'D"M#KIY:`MV7:WHX*VP7F
M]2=4`]:1^^1Q/#QB@(LC2@%`*`4`TH#W1K?(D\4IZ6_A%'1)_@_9D#Q4!<46
MW,QNE6G:.`??%@:I/C2.0'B\-`2%`*`VEVS_`%+MG\XN/]-=J'R_XA]B._T/
M^F6^V7WF7Y6N2PH!0'8AUQK7LW%HUTUZ%*3KIRUZ2-:%RE*/LMHJX\ZZ`''%
MK`X@+4I0!X<M2=.5-@E)R]IM^<ZJ%HH!0"@%`*`4`H!0"@%`*`4`H!0'4ZRV
MZDI6D'Q*'!0\QH"*>@N(U4WJM/'APZQYP#Q'EH"$<]^OR*T/D/BH#A0':VRM
MP\!H/LCP'/3GX:`T_P`\R>YOW^^VMMP18D6YS8A$<J2Y(#+[B"MUW@L!?V*=
M!X]:GL:Q%6XSEMDXKR'EFL:CDSS+UB#Y+<;DELZ:/>S'%;:5"!%5`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`Q/O-^J#/]^0/Q$VMW3_QW]E_0<SXM_I<?WR^
M[(U<J9/-3ZB]P?\`4?<'_-]N_P"!IKD?$?X]O['_`#'T%\'/Z1F_[F'W$;X5
MSIZ^*`4`H!0%1R/F^F*`'F?.?=H"E`*`4`H!0"@/G+WN_P#W)M'^3[=_Q*[U
MT>D?PLOWC^:)X?\`$C^NV_\`;1^_,U7J4.`%`5`U(`YDZ`>$D\@`.))H$JNB
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ML0NJ6Q[&0]_!N6JRAZUOJW^4A/I<#Y_%64T.FG2*`4`H!0"@(Z5;F9/4K3LW
M#R6GPG3Z]/`*\_.@+=DP'XW%20I'PB-2CV=>*3K[%`>,`\/+X?H\U`=[,5Y]
M82T@JX@%7)"?X2N`!T\'.@+ABVEEG13I[97A21HVD^#0<U<?'0$MH!IH!PY>
M0:::#R4!6@%`*`VEVS_4NV?SBX_TUVH?+_B'V([_`$/^F6^V7WF7Y6N2PH!0
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M?1Q9UC/2'G6""A2U$$U0&OVR^ZV=;D[L[UXU>(L2#AVV^X.4X)8Q$V]RN`)_
MS#*LC,>X+W+N%]D8MD%R<;G/>LVZ'`9=C$H)7HE74!";2=X+)=PCW8/G*T8_
M&&]^U&Z>?Y/\V&:HV:XX#<,0@08EG#LM[LX$E[(76Y!?[18=0A(4DZ@@71M1
ME.\=_P!X-U\+S>^[:3L7VUFXA;V?\+87DMDOUV7G.+1\IMTAZ?=,WOL"*BSH
M=5'>0F,HR2D.)4T/1JO0"VML-_\`),Y/=M3<+5CL5>\]MWVF9$B"J:5VIS:>
MXH@6Y%H2[+=*$R%N!,SMPX4KT2GH)TI1@LW:'O*YYN!WBLJVFN-LQY>/6B];
MZ0_XKB688W<[%9MJ,TM&(8_>F,POURDXKN6<FFW)3$^-9V&W;.^$E\I2H!1I
MKL!DK9#=/<+<K-MW8U_@1;=B&#Y_GN#X\F/M[D]I9GC$<OF8[%FL[CW'(YN/
MY7,=C0%KFQ(ENBJBNK`*B$D$^CL!=N\FX&38A(VOQ;#$8Q&RC=O<!6"VG(<U
M1<'\5QKU+%,BS&=,FV^US+;.OEYN$''%Q+5;D2H@ES74]3R4H4E2C8,-7SO#
MY]C&RG>FR2Y6W#[MN1W9[M<L<7=+%"O3N!9K<$XYB>56R=%L:KF]?($^);\M
M;B72T(GO.Q[C'6VB0I*T]-`;+;:7;([[A5GN^6*4;Y-,U<D.8/?]MWD--SI#
M,5N3A>476]7VS2$QVT]0?DK[74.)"4J`H"^J`4`H!0"@*CG[!]PT!;LEE#CK
MFO`AQ?%.@^N//AH>5`="8R$G4ZJ\0/`#S@<Z`]*>8`X`$<!P'M51[@:$9G^M
M^4?W_=/Z6Y72V/P(?97S'CNJ?U+(_?2^<MNLQH"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0&)]YOU09_OR!^(FUNZ?\`CO[+^@YGQ;_2X_OE]V1JY4R>:GU$
M[@_ZC[@_YOMO[MC2*Y'Q'^/;^Q_S'T%\'/Z1F_[F/W$;XUSIZ^*`4`H!0%1R
M/F^F*`'F?.?=H"E`*`4`H!0"@/G5WO674;B6-]3:TL/XC$;8>*%!MYR/<KEV
M[;:M-%+:[9'4.8ZAXZZ/2&GC22Z+C^5+T'B/Q)A..MV9M/DEC*CZ-DI55>.T
MU2/#G]'MU*'GQ==@PZ\7\I<9:]5A$\9TI)2T4@CJ[!O@N0K3['T?&16.Y>A;
M33VLDL'2LO.:G;7+9;]IK93JXF:[#AUGL(2XVUZW.`U5.DI2I:5?[NUQ1'3Y
MM5>6M.Y?G<5-RX([+!T;%PDI+UK_`-9KYET%U+)*5$GZU7[H.OLFL&XE:*C[
M#%_BK96XA62%H0IR[6QM"2I:KA#"4I&I4?6&SP`XG0"K;C2@Z\&9<=-Y-M+:
M^\C\Z-M5>^5YS42>AO8SC52@H!0%02*#IKTD7-M,6=Z13V+Y/!YL`$GE]T3[
MUP>T?+5\;DH]AJW\.U?V^S/BOI1:,VURX)*EH+C/@?:!+?'CHL<2@@<]:V(W
M%/M(:_BW;#K)5AQ1&U>:Y6A04`H!0%-!RT&GBT&A\XY&@/.8D4GJ,=DGQ]FG
MZE`=Z4I0-$I2D>)(`'M#04!RH!0"@%`*`SW8,[P;;_;NSW?/<TQ/![4_-N4>
M/<<OR*TXY"D2!+=46(\B[RXC<AX)()2@J4`==*C[F+DY65*&+;N7)T6R,9/S
MT6SRG5V-;T70M$M9>N9F+A8KG)*=^["U%OF>Q.;BF^I59E6TWBSY!;8=YL%V
MM=]L]P93(@7:RW")=+9.87[UZ)/@NOQ9#9\:%D:UI7+=RU-PO1E":=&I)IKM
M3VHZ+$R\3/QX9>!=M7\2XJQG;G&<)+C&46TUUIGAMN68K>;U?,;M&3X]=<CQ
MA3"<EQ^VWJW3KWCQE`F,+Y:HLEV=:C(`]`/MME7@UJZ=B_;MQO7(3C9G7EDX
MM1E3ZK:H]FW88,?5=+R\N]@8F3CW<_&IWMJ%R$KEJN[O(1;E"O1S)5%SRO%;
M)=;'8;UDV/6>^90\]'QFRW6\VZWW7(I$8-F1'L5OER&I=V?8#J>M$=#BD]0U
M'$4A8OW+<KMN$Y6X>TTFU'KDTJ176Z(KDZIIF'E6,',R;%K.R6U9MSN0C<O-
M;U:A)J5QJJJHIM57$CGY&`;@HR/#I,G$LT38;C;&,NQA<NUWU5CN\&;&OEF8
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M'FE=G.,;:C]9S;45'_4W3K/9MYF6TM]@(QS:G,<`R"W8M;X<<6;!LFL=^;L-
MKU5'@(>CVB?-7!BJ4V4-ES0*((!)K+?P\O%2>3:N6XRW.4913XI52-#2O$7A
M_793AHF?AYD[<4YJQ>MW7%2JHN2A*7*I--)NB='0\<7<'9+%<ENN'Q,]VMQO
M+[KDDFXWK%D9;BUJR.=E]X3&=E2[C957%FXNY!=4)9*BMOMWAT<^%7+`SY6?
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MNVR1N4(=MO>23G&D7)"GDNR7B@.`KZ:/$RU>6/W5SOVJJ/*TVN*35:;]IB_\
MD\._R^YJ_P"?P_Y5:GR3O]];[F$TTN25SFY(RJTN5M.K2I4[TXGLKMC+R/=E
M-IP'`I%\4]<,KS]YZVX_%N3F0SH[\B?>+S)DQ[<IR]W%;2E.K4%2'E).I*N.
M.W:O7[BLVHRE==4DDV]E:[-^RC\QO9>HZ=I^'+4<_(LV-/BDW=N3C"VE)I1;
MG)J*4FTHU>VJIO.SYQV5W[Q^\XTW=-M-X\8:>@*OMH@W7'LUM<.8AU4NTOS&
M[?)G)MUP9?8+L5X%M]M:"MI0*=1DOXN5B-+)MSM.2V<T7&O95+I-72]?T+75
M.6AYN)FJU3G[B];O<E=W-W<I<K='1/?1T+;ML[NRVV`_L%:;OLE"@+D3;%+V
M@C7S#T*D3Y$LR[E;)^)&;ZY-NLN?J[(2\TN2Z^>I?4K4U?\`D<YVOS'<W78:
MKS<DN6G&M*4-=>*?"\M0_E$=2T]ZLI\CL?F+/?*:WP[OGY^9=,:5ZC.;[[;#
M3\F4^VPPPT[)DR)#B6F6&&4*>???=<4EMIIEM*EK4HA*4@DG2M1)MI+:VZ+K
M;V)>4G+DX6H2N76HVX)N3>Q)+:VV]R72WN6^A#8[DV-9A:8]_P`1R*Q9589:
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M>Y<I,9$RXO#WC#94XK0Z`Z5AM8]^_7N(3GRJKY8N5%Q=$Z+K-W4-6TK2E;EJ
MF3CXT;UQ6[;NW(6U.X]T(\[7--]$55O@<H^58M+R2X8;%R;'Y.86B$S<KMBD
M>\V]_)+5;I'9>KS[E9&I"[E!AR.W1T..MI0OK3H>(U=Q>5E9+A-8\G13H^5O
MJ>[90NAJFF7=0N:3:R;$M5M04IV5<@[L(NE)3MI\\8NJHY))U5'M1/5B-XJ.
M?L'W#0$$]]]=_"+^V-`==`*`TKW5L$FQ9A<GG$*]3O3[ET@/Z>@Z)!"I+/4.
M':1Y"B".>A!\-3V'<5RS%5]:*I0\K\0X4\34[DVO=79.47QKO7D?1UF.:W""
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@,3[S?J@S_?D#\1-K=T_\=_9?T',
M^+?Z7']\ONR-7-0.)X`<ZF3S6J6U[C[*=T;;R?@6TT>1>([L.\9E<%Y-)AOI
M*'HD%R.U%M##R%`*;>7":#RDD`CM0#H17#:UE1R,UQ@ZVX+E3^5_*?4/PUT2
M_HWAN,\I..5E3[R2:HU%I*":Z'RJOE-H:B#T`4`H!0"@*CD?-],4`/,^<^[0
M%*`4`H!0"@%`6QE>*8OF-K<M&56J)=82P2TA]&DF,Z1H'X,ILID1'QI[Y"AK
MIQUY5EM7[MF7/;DTS0U#3,#5;'Y;/M1N6NBN]/C%K:GV>4U*N7=GMM@EOW2P
M*E9'%2ZIV-:KF6C+AMCDA"6TH9N2D'D5:*&GO5'C4M'5I75R7$HOC_C<>?7O
MA_CX5QY.*Y9$*U4)TK%=5/;\M&6ZMIQA18<;4PXR>S4PM!;4R4<.@MD)+93I
MIIH-*RUKMWF&G*^5QY9+HI1KJ.%"IQ5[U7\%7VIH'N?80&/X3>;]TO!OU"`?
M_&RD*2'!X?5F?1<?/EX(\M73OP@NLUL32\G+]9KDL_6?3V<3-UAQ.S8^D*BL
M%^9IHJX20E<GB-"&M!T1T'Q)`)\)-:<[L[GM;CI\33L;$VVU6Y]9[_)P\A<M
M8S>%`*`4`H!0`\00>(/,'B#YQX:=F\;]Y!3K#'DDKC'U9T\TI!+*SY4^^02?
M".'DK+"ZX['M1'7]/MSK*UZDOD?H+3DPY,-70^TI&NO2OWS:_P"`L:A7NUL1
ME&6YD3=LW+,N6XFOF/-53$*`4`H!0"@%`*`4`H!0'S@W$E[$X[W\!>N_A;(4
M[8JX[%VR'W=+EN%:[E>=H;5E#,]E>>QYD*/'EVU.1/3DRSU/-J*5+:4H#J84
M.TPXZG<\+NWX8DUJD<EN^H-1NN-%RM-T=*4W;]J3WGS7XDGX)POCF\KXVVHW
M/!5S1H1TJ63"<\&%U23R8N*3AWKFKCK.+HW%O?!GU"[OFY/=;Q3NOWC<CN^0
M8N.=WC`!N;D:66K3><?@$XY,NE\R:=;F<D")[]MNTD%<-XJ+;C+K:$=/3V:.
M+U7"UJ_K4</5'S:K=[N.]2?K445LW-?I+?6K?%_1_@3Q'\,]+^&E[Q%X#C#'
M\`X*S+J]2Y:C[ISNWG%7?6E&<O8G5IJ48JE.5?$[N4[B;@[;]Z+9#O!;C[?;
MBX79>^_=]R\<SG<#+!!9P+.[]N%D#^8;0.X>XU-?FMM6*.PQ#(EM,%Q"RIKJ
M3J1Z-XCP\7,T3)TS$NVKES3HVY0MQ]N$8)0N*7&JJ]GE/C?X-^(=>\/_`!,T
M?QSXAP<_#Q?&5W+LY.3?Y5C9%S+N=_A.PU)R7)ZEM<\8U3;C5-FWG[5#;C)M
MV.\=W#<`P?(E8CN!=W]\)F`Y$A0:7:\WQJTXUE&+.+=U"F8\B^V5AEU8]XAP
MJY`@P7@?+L8.D:GEY,>?%CW2FN,).49?(ZGJO]SWA_4?%'Q"\$:)HM]XNO7/
MYC+&NITY,BS"S?L]B=RW&+?16NZJ<W^R>S[)MT-S._7GF>8X<0SF_;K;=KSO
M&%I+;MFRZV8S>;+DT);2D)<8`O-N?6A!![-*@G4Z:G!X[QK.%B:;B8L^\QHV
M)\DN,7.+3\S53?\`[6]=U+Q)K_C77-<Q_P`IK-[4L7\Q:=?=WX6[D+T=M*+O
M8SHMRK2N\U\M5S[H&*=Y;OS,_M*;+9)>YMVS^7/VSN6Y]BO][M%TV,5!?;Q:
M!M*NWQY*8MP3$[(-F&IM_7H2VXEQMX"7N6]>NZ1ILO"$I+#5I*YW<HIJ]7:[
MM=OD==U>!P6'D_"G3OB'XTM_W#6;4O$<\Z4\2>7;O7(2T[E?<1PN1/EFHTHX
M4EN49*49F_O?`GX)<_V7.[-PVQM[EKVVE=W>R+P6UR+=,M#]NQ1+^.-V2`_;
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MY/+$9+9IUKR)>[3N2?\`J?C`3(M5T8<&+M6KYP,,E#P+G8I=\)37K<)Z2_%^
M)&4<C^;O$CRM-=UR\DFTUOYEMVKBMA^?F3:\?_\`Q[\07+%W25\//_(+JNVY
M0N_GN]_-66G"2]SR5[O?M45))[4?:+]IIT?_`.9VYW6/0_P5LR=-0!^M^`Z=
M))Z=>`TKSOP97_S&RZ[>]O/_`.F9]@?W(4_^.>H[J?E-/_\`S8R./[,>Z;5R
MMOLQ@87?^ZW?,N9?Q&5E1[L6&WK#HD6S.6-,?'V=PFKW'9=NN6-W%JX!<AHE
MHZJT`U-/&<<U9=J63'-C9]91_,2C/UN:LN[:I2%.6D7U;2[^VV_X:N:#EVM(
MO>&KVJJ5B5[^46+EB,;?=N-K\RKBK*_S][ZT6X[TCXJ;\XFY<MV^^!D]XP[!
M+5MM!_:`8E8LZ[QR84NY;M[&MSKN_+8E6")$D0PSA]W3&4F4^MP@3.A/3U*2
MI/HVF9"CIV#8A=N2S):7*4,?=:O-)*DF]\UO2X;:[#XX\<Z3<R/%7BG4LO$P
MK7AZ'CBS;R-52<LW3XRN2ES6XQ:]S-Q:DZ^W14JTU]X?VD>[\O;;NAY5;\)D
M.WK.-\UV#8[;!NUOMR;E?[IN6@VYZ99RTXGU^4YC`DN-J;/2MQULZZ*KR_P?
M@1S=?MO)7+C8U;URJHHJV]B?#UTMF_8S[@_N'\5W/#OPHRL?1Y=]K&MRMZ=A
M\C3G=GE^JY6Z>TW9YG%K>Y1?2:P_LM+Y.VGS[?\`[H&1X1F^U*+&O'MZ=K,`
MW,5;DYA$Q#(;9;[!EI<%KESK;(CN9%!:EH4PZM($E75HH*`F_&]N.=BXOB"W
M=MWW).U=G;KR\Z;<:U2:?*Z;>'8>:_VR:A>\-:WKOPIU##S=,5EVM0P\;,<>
M_5F["-J_7DE*+CWL83]5NG.Z[:I:K]X+N[;@]YKOM]_K;?;3:O:#,KW=+3L-
M%D;D[EWU=DO>RB9.*6-Q&4X0F+!ES;A<;@U#<9DMM=*NS;0-%A729[2]6Q=&
M\.:7EYE^_;MUO^[MQYHW:2?JRZ**O2F>7^./`.N_$?XS^.=`\.Z7I>9F3AIJ
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M0BCZBUQ1]*E1S]@^X:`@GOOKOX1?VQH#KH!0$+?\=L^3P%VV\Q1)8)ZVEI/1
M(BN\NVBO@%3+FG`Z:A0X$$5DM79V9<T-_P`_::F;@XV?9[C*BI0Z.*?%/>F:
MQY?LY?+)VLRQE=^MJ-5J;:;";G&;&I)<CH)3)2D<U->EXTBI>QG6[FRY2,S@
M-2\+Y>'6[B5NX^^GZ:XU73Y##A!25)4%)4E12I*DE*DJ2=%)4E0!2H'@0>5;
MR=54YEIIT=4^O84JI04`H!0"@%`*`4`H!0"@%`*`4!Z(L25.?3&AQW9+ZSHE
MME!6H\-=3I[U(\).B1XZME.,=LMB,ENU=O2Y+47*;Z%_C8NLRC9]M@I`=ODE
M:%D#2'"6D%`/$=M(*5@J\B1[)K1NYM'RV]QT>+X?]7FS)-2^K%KY7M%XVV"6
MR[9)*EK2-3$FJ3JO3P-24A`"B.&BAQ/UPJEO-JZ7-Q3+\/I1YL-MR^J_HE_D
M8)S;;/.<[@QL7QG'ILZ[_/<%Q]"TB-&@QT-2TN2YTU_ICQXK96/2*CU:CI"B
M0#*XV9C8\G>N2I#E?E.*UO0=7U:S'3L&Q.67WJ;3V**Y9>M)O8EUU-AMG.YO
MBN$R(.1Y]*9S+)(RFY,:V(:*,7M<I&BD*[%T!^\/QW!JE;H0UU#4-G@:C\[7
M+M].UC+DLOI_2:^@ZSPQ\+]/TF4,[6)1RLZ.U1I[J,N--\VO]5$GN1ND23SY
M^P/:`Y`"H$]4ZRE`*`4`H!0%1R/F^F*`'F?.?=H"E`*`4`H"BE)2-5$`#PDZ
M4!X'9AXAH</LR-?_`*0>%`>!2BHZJ))/A/$T!2@+<R#$[)DK>EPBA$E*=&I\
M?1J8W]B"YH0\VG[%8(\U9K=^Y:?JOU>!'YNF8F='WRI=Z)+8UZ3"L_:;(6)@
M:M[L.=#6K5$M3R8RV4D\!(85U*ZD@_[,K!\G*MZ.;::K+8SE[GAS-C<<++C*
MT]S;2\Z,B8]MI9K*CUF?T7BX!"U!;S>D)A703]PBJZ@M23R4YU'P@"M:YE7+
MCY5LA4F\+0L7%CWM[WMZG3[*?4NHMH^UIX.`'#Q```<*S5JC4HEL6XI52@H!
M0"@%`*`4`H!5`<'&T.I*'4)<0>:%CJ2?8/*JIM;MY248S7+-)Q+;FXZ#JY!5
MT\SZNX?1/X-P_N!59H7FMDB+OZ:O:L-TX/Z"UW6G65EMYM32QS2L$'V/`1Y1
MJ*V$T]J(J4)0?+-4D<*%HH!0"@%`*`4`H!0&R>$66RW_`&_M=NO]ELU_MXF3
MWA`OMJM]X@A],U[I?3$N4:5'2\`>"@GJ\M1>1=NVLISM3G"=%MBVG3AL:.UT
M["P=0T:W8S[%F_8YI/EN0A<C7F='RSC)57&E3(;EOMKMO-H=MEN<M!B^HJM#
MD"(NU*A`%(AFV+95!,0)X=EV?9Z>"M53FI]XI25RM>:OK5XUWU)J6-C3Q_RD
M[5N6*X\K@XQ<.7ZO(URTZJ4ZCH>LMDDQH,*39+-)AVMR.]:X<BU6]^):WHB>
MB*];(KL=3%O>BHX-+92A38X)(%7*[=4G-2DIRWM/?V\2R>%A7+<+-VQ9E9M-
M.$7"+4''V7!-4@UT.-&CMD6VVS)<.?,MMNF3[:IU5MGRX$23.MJI`"9"K=,?
M:7)@JD)2`LM*05@:'6J*Y<C%PC)J$MZ3V/M1?/&QKMZ&1=MVYY%NO).48N4*
M[^233<6UL;BU7I*QK;;(,B=+@VRW0I=T>3(N<J'`AQ)-SDI!2)-QD1F&GI\@
M!1T<>4M?$\>-)7+DHJ,Y2E%;JNM.I<$4M8N+8G.[8M6H7;KK.481BYM=,FDN
M9];J^L\EUQ[';ZY">ON.V"^O6U17;GKW9+7=WK>LJZ^N`[<8DER$KJ&NK92>
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M\0V`EM%Z*HI-W0VD:)$GM0D<M*IWUU))3FE'V=K]7LX%SP,"7>5L6/?_`(ON
MX^]IN[RJ]>G1SUIT'NC1HT.,Q#A1HT*)%:2Q&B0V&HL6,PV.EMB/&80VQ'9;
M2-$H0D)`Y`58VY-RDVY/I>\SVK5JQ;5FQ&,+$52,8I*,5P26Q+@E1+@<9<.%
M<(K\&XPH=Q@RFRS)@W",Q-A26E$%34F)*;=CR&B4CT5I*=1RI&4H24H-QDNE
M.C\Y;>LV<FT[&3"%RQ+9*,XJ49+@XR33\J.UAIF*TS'BLM18\9M#,:/&;;CL
M1V6DA+3,=EE*&F&FD@!*4@)2``!H*.3E+FEMD]Y="$+4%;M)1MQBDE%422W)
M);%3@J$5_AS&_F^19_\`#>._,\N0J7+M'S%:OFF7*6XAY<J5;!$$&1*6\VE9
M<6VI94D$G4"LG?WN=7.>7>K9S5=:<$^A&K_+=-_+2P_R^.L2<N9P[JWR.5:\
MSAR\K;>UMQJ^)[9MNMMRAKMUQMMON-M=0VAVVW&#$G6YQ#*D+9;<@RF78CB&
M5MI*`4:)*01IH*LC<N0GWD&U/BFTZ\:K:;%_'Q<FR\?)M6[F.Z5A.,90V;ER
MM.-%T*E#R6O'\>L7;&Q8]8;$9/9^LFQV6V6?UGLNKLO6?FZ+&]8[+K/3U]73
MJ=--:NN7KUVG?3E.FZK;IYVS#BZ?I^!7^7X]C'YJ5[JW"WS4W5Y%%NG14+Q_
M'76KI'=QW'W8]\=#][CNV2UN,7J0DA2)%Y97$+5UD)6D$+D!Q0(U!U`JO?WJ
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M6[T\FW;MQR;E.>:C%2G3=SR2K*G1S-T6Q'K4E*DJ0M*5H6E2%H6`I#C:TE"V
MW$*!2M"TD@@\"*L[#*U&47&23BU1I[J<&>6!;[=:HC4"U6^!:H#'7V$"V0HM
MN@L=:RXL,0X;3,9D+<45'I2-2=3QJZ4YSES7&Y3?2W5OM9BL8^/BVE8Q;<+5
MB.Z,(J,5V1BDEY$>NK3,5'/V#[AH"">^^N_A%_;&@/#+G0K>V'9TN/$0=>DO
MN)1U:`'T4D]2O8!JJC*6R*;9CNWK5E<UV48KK9',9+8)"PVS=X96HZ!*UJ:U
M4?`"ZE"?W:O=JXE5II&"&?AS:4;D*LF^>A'$$:@CB"/&".!%8^TVJ[*E=3SU
M.M"I866;<XYEH6])CF!<R-$72"$MOJ(][ZVWH&IB0>?4`KQ$5LV<J[9V5YH<
M&0^I:'@ZDN:<>2_39*.^O6MTEU?*:PY7MMD>)E;[[!N-K3KTW2"A;C*4Z\/6
MVO2=B+TYE7H:\E&I>SEVKVQ-*7!G`ZEH6=IK<IKO,=?IQW=C6^+XUV&/ZVB$
M%`*`4`H!0"@%`*`4`H#DE"EJ2A"5+6HZ(0E)4I2CR2E*022:HVDJLJHRD^6*
MK)]!D.Q;>SIP;DW9:K=%5HH1P$JG.I.A&J5:HCA0^RU5Y*TKV9&.RWM9.X6A
M7KU+F5ZEKA^D_-N\IEVVVBWVA@1[?&;81H.M6G4\Z1]<\\K[HXKSG0>#2M"=
MZ=SV]YU&/C6,2')CQ45\K[62C;;CJPAI"G%J/!*023[0X#R\JQ&RHRD^6*JV
M7)#Q\^BY.5IX>P;5^XXX/!Y![=6NXDFD2%K!Z;K\B+MA*,,@1M&DI3H$)`""
M!]DGZ[V>-8FV]Y(1C&"Y8I*/47$Q<6G-$NZ-+\!&O9D_PB=4>S5"XD?+X_H]
MF@%`*`4`H!0%1R/F^F*`'F?.?=H"E`*`4!XW9B$<&_34/#]:#_\`E0$>XXMP
MZK43Y/`/,*`ZZ`4`H!0"@.*_>.?@W/M%55;UVELO9?882J06XYE[Q52@H!0"
M@%`*`4`H!0"@%`=$B-'E-]G(:2X..AY+3Y4+'I)(I%RBZIF*[9MWE2XD_G\Y
M:DZP/,:N0R9#7/LCH'D#R:<'!^[Y*V874]DO:^0BK^G3@G*T^:/#I_S+?(()
M!&A2="#P((\!!X@UE(ZC%"@H!0"@%`*`4!M+MG^I=L_G%Q_IKM0^7_$/L1W^
MA_TRWVR^\R_*UR6%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`\LV="MD5
MZ?<9<>!"825/2Y;J&&&TZ'BIQ9`UTY`:D^"KHPE.7+%-R9CNW;5BV[UZ2A:6
M]MT7^.HPW>=R([J5_P"'DB0V_JXU<GT$-J0OTD+C,*"5*!2K4*7IYJVH8S3K
M=\WI(2_KD'%/"]9->TUL[4F8PES)4]Y4B8^[(>6=5..K*CY@#Z*$C7@``!6R
MDHJBV$#<N3NRY[C<I=?T'F^G52PNBRY;=K-TLI<];A<`8<A2B$CC]X=XK9/'
MD-4^2L<[4)K=M-_$U+(Q/57K6OJOZ'T&7;-D]JO8"67NPE::JA2"$/:GX%7O
M'T_P>/DK1G:G;VO<=)C9^/E;(.ESZKW^3CY"X:QFZ.!!20%)4"E25`%*DJ&B
MDJ2>"DD<P>!H'1JC1B#+MGK%?B[-LQ38;HH%12TCJM<EPZ<7HJ?2CJ4>:FM!
MXTFMZQFW+>RYZT/E.9U+PQB9=;N)2SD=7LRKQ71Y*&M&18E?\5DF/>8#K"5$
MAB8V"[!D@'@6921V9)'UIZ5CP@5+6K]N\D[;VG!9NG9>GS[O*CR\'OB^Q^DM
MNLQHB@%`*`4`H!0%"=.-`VEM>XN^Q87=[T$/*1ZA!5Q,F0@A3B?]W9/2MWJ'
M(G1/EK6NY-NWZN^1*8>DY.7ZS7)9XOI[$9ELN,6FQH!BL=I)TT7-?T7(/C[-
M6@#*#XD@>4FHVY?G<V/<=7B:=BX<?=JMQ_I/:_\`(N#GP'$\!P&IU\PYDUAH
MS?["=A6*0_TN228S//I(';+'B"3J$`Z\S5DII;%M9MV<.=SUKFR)=4:+'AHZ
M([:4#ZY1]):_*M9&IK'*3EO)2W:MVE2VJ?.>BK3(<T<_8^F*`[:`]4>8]'/H
MJZD>%M7%/L>(T!-,367]$Z]FYRZ%$<>'UJAP4/:-`>R@%`*`4!4<CYOIB@!Y
MGSGW:`I0"@(^8]R:2>&G4O0^^X\$\#RTH"/H!0"@%`*`4`H#BKWB_*A8_P#L
M-56]=I26V+[#"9&A(/,<ZD%N1S&\I52@H!0"@%`*`4`H!0"@%`*`4!;&0P4A
M`G-`!06EM_\`?!1(0YPX=6HT/C'&LUJ>WE>XBM1L1Y>_BO6K1^7I+4K8(@4`
MH!_TGV!S]J@,59?NYC>,*<AQ5B^W5'HJBP74^K1UZZ$2YR0XTA2=>*$!:_&!
M6Y9P[MW;+U8<?\B#S]?P\*L+?O;ZZ$]B[7_C@,0W;QO)RW$EJ%BNR]$B)->2
M8SZSPZ8DXAMI9/V*PA7BUI>P[MK:O6AU>@:?K^)FM6[GNK[W)O8^I/=YS*OB
M\NFGEUY:>/6M,G=YM/MJA2,,M74".IV>XG4::I7-?Z2/&"!41E_COR'>Z%7^
M66Z\9?>9?5:Q+B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%"0E)6HA*$@J6M
M1`2A*>*E+4>"$I',G@*#KZ#!>;[[8[CA>@X^&\DN[?4A3C+O3:(;@.A#\M&I
ME.(/-#7#]^*D<?3;M[UIOEM_*<CJWB[`PG*QB>_OK97=!<:OI[$:\O-;@[KS
M1.N\MU-M"SV+DA*XUHBI)T4+=`1P?6`??`*)/OEU).>+@1Y;:K<^5]K./C9U
MOQ)>5[)E)6-Z;JH17^F/3V[^LRHK$9=N@Q&XKOK[<>*RTI24%M[[DVE/7V74
ML%)`Y`ZBHY7E-MM4;.K>EW,6Q"-I]Y&,4NO8J;B!(*20H%)!T(4""".8((!%
M7FEN='O*54"@*I44D$<%`@I4"04J'$*20000?#5.W<-VU;R_+'G<^`$1[DDW
M"*G1(=*@F8TGEP</HOA(\"N.GAK!<L1DZQV/Y"7Q=7NV?5O^O;X]*])E>VW>
MW7=GMH$E#VGWQHD)?9)^M=:/I)/'GQ!\!K4G"4'229T5C)LY,>>RZKAT^8DJ
ML,YYY<2+/C.0YT9B7%>!2['DMI>96"-/2;6"G4>`\Q58MQ?-'9(LN6K=Z#MW
MHQE;>]-)KY3`>6;',/%V=B$@1G#U+59IKA,=9'$)ARSJMGAR0YJG]\*DK&H.
M/JWELXKT'&ZCX2A*MW37RO\`Z<MW_"^BG!^<UXN5KN-GEK@W2%(@2V]>IB2V
M6U$`Z=39]ZZ@Z\%))!J4A<A-<T'5'$W\>_BW':R(N%Q=#/!5YA%`*`4`H#+.
MWN/0I$=R]3&4274REL1&G4A;;(9">MXH.J%.J6K0:CT0*C\R\T^ZCPVG3Z%@
MV9VWF7$I2K2-=RIO[69;J.>UG3[R2AVJ5,T4$AIG4:O.`@'^`GWRSI[%6N44
M;%K%NW=M*1Z^DNR';(L+BA':.Z:%YP>G_P#(`=$#S<:Q.<FB3M8UJUM2]?B2
M!.M6FP*`4!S1S]CZ8H#MH!0"@)FW2%J465DJ!05H43KT])`*==>1UH"7H!0"
M@*CD?-],4`/,^<^[0%*`4!#2?O[GG'VHH#HH!0"@%`*`4`H!]'T<J`QS?[([
M%>=EQVU.175%Q70.,=:CZ06`/O95J4GV#6Y:N*2Y>D@\O%E:DYQ5;;^0M:LQ
MI"@%`*`4`H!0"@%`*`4`H!0$7>?ZLE>1+>G_`&S0J^W^(C5SOX2?53Y_\RP:
MVSG10"J@U1WCS;(4Y!<,7C3E0;1%9B=;4/J9>F&3%:D+]:D)(=6V"[H$`A.@
MX@ZU+X./:[M7FDY/<<+X@U'+_-RPX3<<>,55*J<FTGMZNHP+YN%2.U[SF!IK
MPTU\G`_N&E:#?LWHV=[N\_,<HR^U8;ZT[*QZ6F9VTF>%O"U(BQ'9*O5)2SVA
M)#)2&=2./UO.HC4XV+5F60DN\7#I.S\(W=0S-2MZ<I-XTZUYMO+15V/R4H?6
M.%$8M\.+`C([./#8;CLHX:A#20D:D`:J.FI\9-<?*3E)R>]L]_M6H6;<;-OV
M(JB/35ID%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"H!/`4'SF,\VW6Q3"4N,29/
MSG>$CT;-;G&W)"#IP]=>U+,)'$:]1Z].236YCX5[(VI<MOB_HXD%JGB#`TM.
M$GWF2OT(M5_XGNCY:OJ-0,VW8RO-2N/(D_-EG)/19[<MQMA203T^NOZAZ<O3
MGU:(\214WCX=C'VQ5;G%_1P/,]7\1ZAJK=N4N[Q7^A%M)_:Z9>79P1-;6XQ9
M[K&F7:Y1A,>AS1&C,/:*BHT80\75L>]><ZE\.K5(`Y>$:^H7[D)*W!TJJU\I
M*^%M-Q,FU/*R(\TH3Y8I^RMB=:=+,]H]'I2D)2E.@"4@)2E(\``T`2!X*B-^
MU[SO*+8DDDN!,LG[DWI]@C]Q(JY;#,MR(:]6N'*B29"VDID,L.NH>1Z*R6T%
M6CFG!P'I\/&KH2:=.@U,S'LW+<KDDE<C'>8N]WP^?PUM'.(4`H!0'='DR(CR
M)$9YQAYL@I<:64J&G@U!XCR<C5&DU1EUN<[<U.W)QDNE&3;)N$?0CWMK7D!/
M8''Q:R(_`'RJ1IYJU9XRWPW\">Q=9=5;RUL^LOI,FQY,:8RB1$?:D,+`*7&5
MA:3PX@D'5)\8.A%:K33HR>A.%R*G;:<7P.ZJ%Q#WO'[-D<14*]0&)S)UZ%+'
M3(84>'7&DI^[,*'[T^<&K[=R=J7-!T-7+PL;.M=UDP4H?*NQ]!K?EVRMTMH=
MFXRZN\0QJLP'`D71A.O$-]/2U-0D>+I7I];4M9U"$J1N[)<>@X;4O"N1CIWL
M%][:6WE?M+LX_.80<:<9<6T\VXRZVHH<:=0IMQM8YH<;6$K0H>(@5()I[5N.
M3E&4).$TU-;&GL:?6N@X54M%`*H]JH#83;*%)F8\E+#94!/FZN$:-)]-`)4O
MEP\FM1.:UW[;W'<^'+-R]I\5;W<\MO1OXF985DC1M''M)+PT(*DZ-(//T$'7
M4@^$U'N;Z-QUEG#MV_6GZTB9^E5AN"@%`*`4!S1S]CZE`=M`*`4!(VW^4#\$
MO[:@)^@%`*`J.1\WTQ0$B1:-3]TNO,_[&%_W]`4TL_PEU_[&%_W]`-+/\)=?
M^QA?]_0$6^FP]LOJ=O75J->F/`(Y#EK)!Y4!T]./_"WOXO;_`)50#IQ_X6]_
M%[?\JH!TX_\`"WOXO;_E5`.G'_A;W\7M_P`JH!TX_P#"WOXO;_E5`.G'_A;W
M\7M_RJ@'3C_PM[^+V_Y50#IQ_P"%O?Q>W_*J`KTV#0_=;UIH=?XO;O>Z>EK_
M`!K7ITY^"A1TZ=WR>@Q_>T;>E]73(R)$CJ^ZFW0[2XUU<=>M+L]IKK\?0?/6
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M+IGULC]6'[94,[9:C_S+<'\QXQ_J"E;_``AYWZ`XZ93VLC]6'[9J1NC$[OZL
MWNQNU^WM:GEJW=LW;,2V^D0@/4&.R[)V9FL:0HEO3JU0-%:Z:CC4QAO._+QY
M(V>7KE*OR1."UF'AMZC<[^YGJ[2->6W9:]E4HW=3^0Q_ZGW;O_Z+?S_DS;7_
M`%Y6S74?JV/UI_LD9R>%?^KJ/_I6/^\2EHB=V%,QOUZ_;Y.,ZC03,2P!B*%>
M`OJA9K(?4C7P``>/A5EQZER[(V?)*7TQ,MB'A/O5SW-1:KTV[*7EI=;-Q-EV
M-H4YQ8%8Q=-P'G@Q<O46YMAQ&-:%(^;9/:]3UNR.6^@AK4IZ6U:JT!T&IJ%S
MGD_EI=XH4IT.5=_6DCO/"\=&6K67@SR7<]:BE"VH^R][C-O=U=INSTV;X:[?
M%H7RNH`]6'39OAKM\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A
M?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\KH!T
MV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM
M\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\K
MH#&NYC*EV=9M]QS^/;PVOYQ1A]EQN9=U-:'K/:7"_P`&6ECHYB,DKTUU.E;>
M&[?>>LH.==G,VE\B:\Y!Z[',>*^YED1L4]?N8PE.G_%.,J?9VFESD;9OM7.U
MO.[G;=HKM>UQK"NU[7J/5VG7EG:=IU<^KCK4_7+IL5KE[94\GJGEW)HM76YG
M<W3[NU7RUN5\^TZ_5ME_[9W:_P"6L)_U92N7PM>>7[)BY-`_ZF;_`.G:_P"X
M9SVM9VV39[B+3<<^=8^<CVJKI9<:CO!WU1G@VF'?Y+:F^C3B2#KX-*BL_O>]
M7>**?+T-OI?%([CPNM/6%<_*2ON'>[>>,$Z\JW<LI*GE,EAO"]>$S+/S99?%
MQYW;3E6CZW4=+[KC/S+TDC';Q#LAI+RDIU/3U6ZS@Z>Q="--:KZW49EW=/TO
MD])PG-X=ZC,[27E(;]5D=91;K,5A'9*ZB@*NB4E>G+4@:T7-5;MYCO\`==S/
MF<N7EX+TF+BSMQJ?_,<]Y_V-C?Z>K:][PCYWZ#G4L#ZU_P#5A^T4[';C^T<]
M_,V-_IZGO>$?._0*8'UK_P"K#]H=CMQ_:.>_F;&_T]3WO"/G?H%,#ZU_]6'[
M0[';C^T<]_,V-_IZGO>$?._0*8'UK_ZL/VAV.W']HY[^9L;_`$]3WO"/G?H%
M,#ZU_P#5A^T.QVX_M'/?S-C7Z>I[WA'SOT"F!]:]^K#]HN3&V<8]<'S#<=P^
MTU';:6;&_4^CA_*^J_=AT^?TO%QK'=K3WBC3M?H-S"5OO?\`VDLCF^S&GE]:
MAF5*+!TIZY-[*]!U$0K<D%6G$A(N"@./@U-:+I79N.H5:>MO.71CWY1?/B=N
M^74*@(Q_P2+Y\3MW[G\>JCIT@P]NDC9HL$9/)O:;T4?Q95GA6E5]2/K2XD7!
M#*F`?!)(2?`:W\/\U7W7L=>XYCQ#_).3_P#8?Q5-G)3O/+T4^T:Z^K[/?VON
MG_RYAO\`JFI:N3PM^>7H.)Y=%^OE_J6_^X/5]GO[7W4_Y<PW_5-*Y/"WYY>@
M<NB_7R_U+?\`W"<QUG8I-T8-VN.XS\77WMRLV.Q8`7J-#+7;+],F*:\8"0/&
M=*Q7GF<GNU!/J;K\J1M82\.K(7YF62[?^J,5&O7R2E*G8;9PT81ZG&^:)-Q%
ML[)'JGS="LYA]GIP[$M7`)\_A\=04^?F?/7FKMK4].Q^X[E?E>7N.CEI3KW'
MHZ,9_*<@^(VS](U:91T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ
M1H!T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ1H#L0C&N.DG(/!_P"!M@\?_P"P-`<^
MC&ORF_\`Q*V_+Z`=&-?E-_\`B5M^7T`Z,:_*;_\`$K;\OH#W048]VX[.1?"K
MLU>_AVX)TZN/%,XG6@)GILWPUV^+0OE=`.FS?#7;XM"^5T`Z;-\-=OBT+Y70
1%0FS<?NUVY?DT+QC_>Z`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
